# Patent

## Title
Receptor based antagonists and methods of making and using

## Abstract

The present invention provides a fusion polypeptide that forms a multimer that is capable of binding a cytokine to form a nonfunctional complex. It also provides a nucleic acid sequence encoding the fusion polypeptide and methods of making and uses for the fusion polypeptide.

## Background
This application is a Continuation-in-Part of U.S. application Ser. No. 09/935,868, filed Aug. 23, 2001 now abandoned, which is a Continuation-in-Part of U.S. application Ser. No. 09/787,835, filed Mar. 22, 2001 now abandoned, which is a §371 U.S. National Stage Application of International Application No. PCT/US99/22045, filed Sep. 22, 1999, which is a Continuation-in-Part of and claims priority of U.S. application Ser. No. 09/313,942, filed May 19, 1999, now U.S. Pat. No. 6,472,179, which claims priority of U.S. Provisional Application No. 60/101,858 filed Sep. 25, 1998, now abandoned. Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application.


BACKGROUND OF THE INVENTION
Although discovered for varying biological activities, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM) and interleukin-6 (IL-6) comprise a defined family of cytokines (referred to herein as the “CNTF family” of cytokines). These cytokines are grouped together because of their distant structural similarities [Bazan, J. Neuron 7: 197–208 (1991); Rose and Bruce, Proc. Natl. Acad. Sci. USA 88: 8641–8645 (1991)], and, perhaps more importantly, because they share “β” signal-transducing receptor components [Baumann, et al., J. Biol. Chem. 265:19853–19862 (1993); Davis, et al., Science 260: 1805–1808 (1993); Gearing et al., Science 255:1434-1437 (1992); Ip et al., Cell 69: 1121–1132 (1992); Stahl, et al., J. Biol. Chem. 268: 7628–7631 (1993); Stahl and Yancopoulos, Cell 74: 587–590 (1993)]. Receptor activation by this family of cytokines results from either homo- or hetero-dimerization of these β components [Davis, et al. Science 260: 1805–1808 (1993), Murakami, et al., Science 260: 1808–1810 (1993); Stahl and Yancopoulos, Cell 74: 587–590 (1993)]. IL-6 receptor activation requires homodimerization of gp130 [Murakami, et al. Science 260: 1808–1810 (1993), Hibi, et al., Cell 63: 1149–1157 (1990)], a protein initially identified as the IL-6 signal transducer [Hibi, et al., Cell 63: 1149–1157 (1990)]. CNTF, LIF and OSM receptor activation results from heterodimerization between gp130 and a second gp130-related protein known as LIFRβ [Davis, et al., Science 260: 1805–1808 (1993)], that was initially identified by its ability to bind LIF [Gearing et al., EMBO J. 10: 2839–2848 (1991)].
In addition to the β components, some of these cytokines also require specificity-determining “α” components that are more limited in their tissue distribution than the β components, and thus determine the cellular targets of the particular cytokines [Stahl and Yancopoulos, Cell 74: 587–590 (1993)]. Thus, LIF and OSM are broadly acting factors that may only require the presence of gp130 and LIFRβ on responding cells, while CNTF requires CNTFRα [Stahl and Yancopoulos, Cell 74: 587–590 (1993)] and IL-6 requires IL-6Rα [Kishimoto, et al., Science 258: 593–597 (1992)]. Both CNTFRα (Davis et al., Science 259:1736–1739 (1993) and IL-6Rα [Hibi, et al. Cell 63:1149–1157, Murakami, et al., Science 260:1808–1810 (1990); Taga, et al., Cell 58:573–581 (1989)] can function as soluble proteins, consistent with the notion that they do not interact with intracellular signaling molecules but that they serve to help their ligands interact with the appropriate signal transducing β subunits [Stahl and Yancopoulos, Cell 74: 587–590 (1993)].
Additional evidence from other cytokine systems also supports the notion that dimerization provides a common mechanism by which all cytokine receptors initiate signal transduction. Growth hormone (GH) serves as perhaps the best example in this regard. Crystallographic studies have revealed that each GH molecule contains two distinct receptor binding sites, both of which are recognized by the same binding domain in the receptor, allowing a single molecule of GH to engage two receptor molecules [de Vos, et al., Science 255: 306–312 (1992)]. Dimerization occurs sequentially, with site 1 on the GH first binding to one receptor molecule, followed by the binding of site 2 to a second receptor molecule [Fuh, et al., Science 256: 1677–1680 (1992)]. Studies with the erythropoietin (EPO) receptor are also consistent with the importance of dimerization in receptor activation, as EPO receptors can be constitutively activated by a single amino acid change that introduces a cysteine residue and results in disulfide-linked homodimers [Watowich, et al., Proc. Natl. Acad. Sci. USA 89:2140–2144 (1992)].
In addition to homo- or hetero-dimerization of β subunits as the critical step for receptor activation, a second important feature is that formation of the final receptor complex by the CNTF family of cytokines occurs through a mechanism whereby the ligand successively binds to receptor components in an ordered manner [Davis, et al. Science 260:1805–1818 (1993); Stahl and Yancopoulos, Cell 74: 587–590 (1993)]. Thus CNTF first binds to CNTFRα, forming a complex which then binds gp130 to form an intermediate (called here the αβ1 intermediate) that is not signaling competent because it has only a single β component, before finally recruiting LIFRβ to form a heterodimer of β components which then initiates signal transduction. Although a similar intermediate containing IL-6 bound to IL-6Rα and a single molecule of gp130 has not been directly isolated, we have postulated that it does exist by analogy to its distant relative, CNTF, as well as the fact that the final active IL-6 receptor complex recruits two gp130 monomers. Altogether, these findings led to a proposal for the structure of a generic cytokine receptor complex (FIG. 1) in which each cytokine can have up to 3 receptor binding sites: a site that binds to an optional α specificity-determining component (α site), a site that binds to the first β signal-transducing component (β1 site), and a site that binds to the second β signal-transducing component (β2 site) [Stahl and Yancopoulos, Cell 74: 587–590 (1993)]. These 3 sites are used in sequential fashion, with the last step in complex formation—resulting in β component dimerization—critical for initiating signal transduction [Davis, et al. Science 260:1805–1818 (1993)]. Knowledge of the details of receptor activation and the existence of the non-functional β1 intermediate for CNTF has led to the finding that CNTF is a high affinity antagonist for IL-6 under certain circumstances, and provides the strategic basis for designing ligand or receptor-based antagonists for the CNTF family of cytokines as detailed below.
Once cytokine binding induces receptor complex formation, the dimerization of β components activates intracellular tyrosine kinase activity that results in phosphorylation of a wide variety of substrates [Ip, et al. Cell 69:121–1132 (1992)]. This activation of tyrosine kinase appears to be critical for downstream events since inhibitors that block the tyrosine phosphorylations also prevent later events such as gene inductions [Ip, et al., Cell 69:121–1132 (1992); Nakajima and Wall, Mol. Cell. Biol. 11:1409–1418 (1991)]. Recently, we have demonstrated that a newly discovered family of non-receptor tyrosine kinases that includes Jak1, Jak2, and Tyk2 (referred to as the Jak/Tyk kinases) [Firmbach-Kraft, et al., Oncogene 5:1329–1336 (1990); Wilks, et al., Mol. Cell. Biol. 11: 2057–2065 (1991] and that are involved in signal transduction with other cytokines [Argetsinger, et al., Cell 74:237–244 (1993); Silvennoinen, et al., Proc. Natl. Acad. Sci. USA 90:8429–8433 (1993); Velazquez, et al., Cell 70: 313-322 (1992); Witthuhn, et al., Cell 74:227–236 (1993)], preassociate with the cytoplasmic domains of the β subunits gp130 and LIFRβ in the absence of ligand, and become tyrosine phosphorylated and activated upon ligand addition [Stahl et al., Science 263:92–95 (1994)]. Therefore these kinases appear to be the most proximal step of intracellular signal transduction activated inside the cell as a result of ligand binding outside of the cell. Assay systems for screening collections of small molecules for specific agonist or antagonist activities based on this system are described below.
The CNTF family of cytokines play important roles in a wide variety of physiological processes that provide potential therapeutic applications for both antagonists and agonists.
SUMMARY OF THE INVENTION
An object of the present invention is the production of cytokine antagonists that are useful in the treatment of cytokine-related diseases or disorders.
Another object of the invention is the use of the disclosed cytokine antagonists for the treatment of cytokine-related diseases or disorders. For example, an IL-6 antagonist described herein may be used for the treatment of osteoporosis, the primary and second effects of cancers, including multiple myeloma, or cachexia.
Another object of the invention is the development of screening systems useful for identifying novel agonists and antagonists of cytokine receptors.
Another object of the invention is the development of screening systems useful for identifying small molecules that act as agonists or antagonists of the cytokines.
Another object of the invention is the development of screening systems useful for identifying novel agonists and antagonists of members of the CNTF family of cytokines.
Another object of the invention is the development of screening systems useful for identifying small molecules that act as agonists or antagonists of the CNTF family of cytokines.



BRIEF DESCRIPTION OF THE FIGURES
FIG. 1: Ordered binding of receptor components in a model of a generic cytokine receptor. The model indicates that cytokines contain up to 3 receptor binding sites and interact with their receptor components by binding first the optional α component, followed by binding to β1, and then β2. The β components for many cytokine receptors interact through membrane proximal regions (shaded boxes) with the Jak/Tyk family of cytoplasmic protein tyrosine kinases. Only upon dimerization of β components is signal transduction initiated, as schematized by the tyrosine phosphorylations (P) of the β components and the Jak/Tyk kinases.
FIG. 2: CNTF inhibits IL-6 responses in a PC12 cell line (called PC12D) that expresses IL6Rα, gp130, CNTFRα, but not LIFRβ. Serum-deprived PC12D cells were incubated +IL-6 (50 ng/mL) in the presence or absence of CNTF as indicated. Some plates also received soluble IL6Rα (1 mg/mL) or soluble CNTFRα (1 mg/mL) as indicated. Cell lysates were subjected to immunoprecipitation with anti-gp130 and immunoblotted with anti-phosphotyrosine. Tyrosine phosphorylation of gp130 is indicative of IL-6 induced activation of the IL-6 receptor system, which is blocked upon coaddition of CNTF.
FIG. 3: Scatchard analysis of iodinated CNTF binding on PC12D cells. PC12D cells were incubated with various concentrations of iodinated CNTF in the presence or absence of excess non-radioactive competitor to determine the specific binding. The figure shows a Scatchard plot of the amount of iodinated CNTF specifically bound, and gives data consistent with two binding sites with dissociation constants of 9 pM and 3.4 nM.
FIGS. 4A–4B (SEQ ID NO: 7). The amino acid sequence of human gp130-Fc-His6(SEQ ID NO: 7). Amino acids 1 to 619 are from human gp130 (Hibi et al., Cell 63:1149–1157 (1990). Note that amino acid number 2 has been changed from a Leu to a Val in order to accommodate a Kozak sequence in the coding DNA sequence. The signal peptide of gp130-Fc-His6 has been italicized (amino acids 1 to 22). The Ser-Gly bridge is shown in bold type (amino acids 620, 621). Amino acids 662 to 853 are from the Fc domain of human IgG1 (Lewis, et al., J. Immunol. 151:2829–2838 (1993). (+) mark the two cysteines (amino acids number 632 and 635) of the IgG hinge preceding the Fc that form the inter-chain disulfide bridges that link two Fc domains. The hexahistine tag is shown in bold/italic type (amino acids 854 to 859). (•) shows the position of the STOP codon.
FIG. 5 (SEQ ID NO: 8): The amino acid sequence of human IL-6Rα-Fc (SEQ ID NO: 8). Key: Amino acids 1 to 358 are from human IL-6Rα, (Yamasaki, et al., Science 241:825–828 (1988). Note that amino acid number 2 has been changed from a Leu to a Val in order to accommodate a Kozak sequence in the coding DNA sequence. The signal peptide of IL-6Rα-Fc has been italicized (amino acids 1 to 19). The Ala-Gly bridge is shown in bold type (amino acids 359, 360). Amino acids 361 to 592 are from the Fc domain of human IgG1 (Lewis et al., J. Immunol. 151:2829–2838 (1993). (+) mark the two cysteines (amino acids number 371 and 374) of the IgG hinge preceding the Fc that form the inter-chain disulfide bridges that link two Fc domains. (•) shows the position of the STOP codon.
FIG. 6: The CNTF/IL-6/IL-11 receptor system. The ordered formation of the hexameric signal transducing receptor complex is depicted schematically. The cytokine associates with the Rα component to form an obligatory cytokine•Rα complex (Kd is about 5 nM). This low affinity complex next associates with the first signal transducing component, marked β1, to form a high affinity cytokine•Rα•β1 complex (Kd is about 10 pM). In the case of IL-6Rα, this component is gp130. This trimeric high affinity complex subsequently associates with another such complex. Formation of this complex results in signal transduction as it involves dimerization of two signal transducing components, marked β1 and β2 respectively (adapted from (Ward et al., J. Bio. Chem. 269:23286–23289 (1994); Stahl and Yancopoulos, J. Neurobiology 25:1454–1466 (1994); Stahl and Yancopoulos, Cell 74:587–590 (1993).
FIG. 7: Design of heterodimeric receptor-based ligand Traps for IL-6. The heterodimeric ligand Trap is comprised of two interdisulfide linked proteins, gp130-Fc and IL-6Rα-Fc. The gp130-Fc•IL-6Rα-Fc complex (upper panel) is shown to mimic the high affinity cytokine•Rα•β1 complex (lower panel). The ligand Trap functions as an antagonist by sequestering IL-6 and thus rendering unavailable to interact with the native receptors on IL-6-responsive cells.
FIG. 8. Heteromeric immunoglobulin Heavy/Light Chain Receptor Fusions. An example of a heavy/light chain receptor fusion molecule is schematically depicted. The extracellular domain of gp130 is fused to Cγ, whereas the extracellular domain of IL-6Rα is fused to the constant region of the kappa chain (κ). The inter-chain disulfide bridges are also depicted (S-S).
FIGS. 9A–9B (SEQ ID NO: 9). Amino acid sequence of gp130-Cγ1 (SEQ ID NO: 9). Key: Amino acids 1 to 619 are from human gp130 (Hibi, et al., Cell 63:1149–1157 (1990). Ser-Gly bridge is shown in bold type. Amino acids 662 to 651 are from the constant region of human IgG1 (Lewis et al., J. Immunol. 151:2829–2838 (1993). (*) shows the position of the STOP codon.
FIG. 10 (SEQ ID NO: 10): Amino acid sequence of gp130Δ3fibro (SEQ ID NO: 10). Key: Amino acids 1 to 330 are from human gp130 (Hibi et al., Cell 63:1149–1157 (1990). Other symbols as described in FIG. 9.
FIG. 11 (SEQ ID NO: 11): Amino acid sequence of J-CH1 (SEQ ID NO: 11). Key: The Ser-Gly bridge is shown in bold, the J-peptide is shown in italics, the CH1 domain is underlined.
FIG. 12 (SEQ ID NO: 12): Amino acid sequence of Cγ4 (SEQ ID NO: 12). Key: The Ser-Gly bridge is shown in bold type. Amino acids 2 to 239 comprise the Cγ4 sequence.
FIG. 13 (SEQ ID NO: 13): Amino acid sequence of κ-domain (SEQ ID NO: 13). Key: The Ser-Gly bridge is shown in bold type. Amino acids 2 to 108 comprise the κ domain. The C-terminal cysteine (amino acid 108) is that involved in the disulfide bond of the κ domain with the CH1 domain of Cγ.
FIG. 14 (SEQ ID NO: 14): Amino acid sequence of λ-domain (SEQ ID NO: 14). Key: The Ser-Gly bridge is shown in bold type. Amino acids 2 to 106 comprise the λ domain (Cheung, et al., J. Virol. 66: 6714–6720 (1992). The C-terminal cysteine (amino acid 106) is that involved in the disulfide bond of the λ domain with the CH1 domain of Cγ.
FIG. 15 (SEQ ID NO: 15): Amino acid sequence of the soluble IL-6Rα domain (SEQ ID NO: 15). Key: Amino acids 1 to 358 comprise the soluble IL-6Rα domain (Yamasaki, et al., Science 241:825–828 (1988). The Ala-Gly bridge is shown in bold type.
FIG. 16 (SEQ ID NO: 16): Amino acid sequence of the soluble IL-6Rα313 domain (SEQ ID NO: 16): Key: Amino acids 1 to 313 comprise the truncated IL-6Rα domain (IL-6Rα313). The Thr-Gly bridge is shown in bold type.
FIG. 17: Purification of gp130-Cγ1•IL-6Rα-κ. 4% to 12% SDS-PAGE gradient gel run under non-reducing conditions. Proteins were visualized by staining with silver. Lane 1: approximately 100 ng of material purified over Protein A Sepharose (Pharmacia). Lane 2: Molecular size standards (Amersham). Lane 3: The Protein A-purified material shown here after further purification over an IL-6 affinity chromatography step. The positions of the gp130-Cγ1 dimer [(gp130-Cγ1)2], the gp130-Cγ1 dimer associated with one IL-6Rα-κ [(gp130-Cγ1)2•(IL-6Rα-κ)1], and the gp130-Cγ1 dimer associated with two IL-6Rα-κ [(gp130-Cγ1)2•(IL-6Rα-κ)2] are shown, as well as the sizes for the molecular size standards in kilodaltons (200, 100, and 46).
FIG. 18: IL-6 dissociates slowly from the ligand Trap. The dissociation rate of IL-6 from a heavy/light chain receptor-based ligand Trap (gp130-Cγ1•IL-6Rα-κ) was compared to that obtained with the neutralizing monoclonal antibody B-E8 (BE8 MAb).
FIG. 19: IL-6 can induce multimerization of the ligand Trap. (A) Two different ligand Traps are depicted schematically and listed according to their ability to bind protein A. gp130-Fc•IL-6Rα-Fc (GF6F) binds protein A via its Fc-domains, whereas gp130-CH1•IL-6Rα-κ (G16K) does not bind to protein A. (B) Anti-kappa western blotting of proteins precipitated with Protein A-Sepharose from mixtures of GF6F±IL-6, G16K±IL-6, or GF6F plus G16K±IL-6, as marked.
FIG. 20: Inhibition of IL-6-dependent XG-1 cell proliferation. XG-1 cells [Zhang, et al., Blood 83:3654–3663 (1994)] were prepared for a proliferation assay by starving the cells from IL-6 for 5 hours. Assays were set up in 96-well tissue culture dishes in RPMI +10% fetal calf serum+penicillin/streptomycin+0.050 nM 2-mercaptoethanol+glutamine. 0.1 ml of that media was used per well. Cells were suspended at a density of 250,000 per ml at the start of the assay. 72 hours post addition of IL-6±ligands Traps or antibodies, an MTT assay was performed as described (Panayotatos et al. Biochemistry 33:5813–5818 (1994). The different ligand Traps utilized are listed.
FIGS. 21A–21D (SEQ ID NOS: 17 and 18): Nucleotide (SEQ ID NO: 17) sequence encoding and deduced amino acid (SEQ ID NO: 18) sequence of fusion polypeptide designated 424 which is capable of binding the cytokine IL-4 to form a nonfunctional complex.
FIGS. 22A–22D (SEQ ID NOS: 19 and 20): Nucleotide (SEQ ID NO: 19) sequence encoding and deduced amino acid (SEQ ID NO: 20) sequence of fusion polypeptide designated 603 which is capable of binding the cytokine IL-4 to form a nonfunctional complex.
FIGS. 23A–23D (SEQ ID NOS: 21 and 22): Nucleotide (SEQ ID NO: 21) sequence encoding and deduced amino acid (SEQ ID NO: 22) sequence of fusion polypeptide designated 622 which is capable of binding the cytokine IL-4 to form a nonfunctional complex.
FIGS. 24A–24F (SEQ ID NOS: 23 and 24): Nucleotide (SEQ ID NO: 23) sequence encoding and deduced amino acid (SEQ ID NO: 24) sequence of fusion polypeptide designated 412 which is capable of binding the cytokine IL-6 to form a nonfunctional complex.
FIGS. 25A–25F (SEQ ID NOS: 25 and 26): Nucleotide (SEQ ID NO: 25) sequence encoding and deduced amino acid (SEQ ID NO: 26) sequence of fusion polypeptide designated 616 which is capable of binding the cytokine IL-6 to form a nonfunctional complex.
FIGS. 26A–26E (SEQ ID NOS: 27 and 28): Nucleotide (SEQ ID NO: 27) sequence encoding and deduced amino acid (SEQ ID NO: 28) sequence of fusion polypeptide designated 569 which is capable of binding the cytokine IL-1 to form a nonfunctional complex.
FIG. 27: Shows that an IL-4 Trap designated 4SC375, which is a fusion polypeptide of IL-2Rγ-scb-IL4Rα-FcΔC1, is several orders of magnitude better as an IL-4 antagonist than IL4RαFcΔC1 alone in the TF1 cell bioassay.
FIG. 28: Shows that an IL-4 Trap designated 4SC375 displays antagonistic activity in the TF1 cell bioassay equivalent to an IL-4 Trap designated 4SC424 (described in FIGS. 21A–21D) which is a fusion polypeptide of IL-2Rγ-IL4Rα-FcΔC1 having the IL-2Rγ component flush with the IL-4Rα component.
FIG. 29: Shows that the IL6 Trap (6SC412 IL6R-scb-gpx-FcΔC1) described in FIGS. 24A–24F is a better antagonist of IL-6 in the XG1 bioassay than the neutralizing monoclonal antibody to human IL-6-BE8.
FIG. 30: Shows that the Trap 1SC569 (described in FIGS. 26A–26E) is able to antagonize the effects of IL-1 and block the IL-6 production from MRC 5 cells upon treatment with IL-1.
FIGS. 31A–31G (SEQ ID NOS: 29 and 30): The nucleotide (SEQ ID NO: 29) and encoded amino acid (SEQ ID NO: 30) sequence of the IL-4Rα.IL-13Rα1.Fc single chain Trap construct is set forth.
FIGS. 32A–32G (SEQ ID NOS: 31 and 32): The nucleotide (SEQ ID NO: 31) and encoded amino acid (SEQ ID NO: 32) sequence of the IL-13Rα1.IL-4Rα.Fc single chain Trap construct is set forth.
FIG. 33: Blocking of IL-13 by IL-4Rα.IL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc. Addition of either IL-4Rα.IL-13Rα1.Fc or IL-13Rα1.IL-4Rα.Fc Trap at a concentration of 10 nM blocks IL-13-induced growth up to  ̃2 nM. At an IL-13 concentration of  ̃4–5 nM the growth of TF1 cells is inhibited by 50%.
FIG. 34: Blocking of IL-4 by IL-4Rα.IL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc. Addition of either IL-4Rα.IL-13Rα1.Fc or IL-13Rα1.IL-4Rα.Fc at a concentration of 10 nM blocks IL-4-induced growth up to  ̃1 nM. At an IL-4 concentration of  ̃3–4 nM the growth of TF1 cells is inhibited by 50%.
FIG. 35: Human IL-1 Trap blocks the in vivo effects of exogenously administered huIL-1. BALB/c mice were given subcutaneous injection of huIL-1 (0.3 μg/kg) at time 0. Twenty-four hours prior to huIL-1 injection, the animals were pre-treated with either vehicle or 150-fold molar excess of huIL-1 Trap. Two hours prior to sacrifice (26 hrs), the mice were re-challenged with a second injection of huIL-1 (0.3 μg/kg, s.c.). Blood samples were collected at various time points and sera were assayed for IL-1 levels (expressed as mean +/−SEM; n=5 per group).
FIGS. 36A–36B: Human IL-4 Trap antagonizes the effects of human IL-4 in monkeys. FIG. 36A: Cynomologus monkeys were treated in three parts as indicated. Human IL-4 (25 μg/kg) was injected subcutaneously twice daily for 4 days and human IL-4 Trap (8 mg/ml) and vehicle were given intravenously daily for 5 days, beginning 1 day prior to human IL-4 administration. Plasma was collected daily and assayed for MCP-1 levels. Results were expressed as mean +/−SEM; n=4. (ANOVA p<0.0007; Tukey-Kramer: Part 2 vs. Part 1, p,0.05; Part 2 vs. Part 3, p,0.05; Part 1 vs. Part 3, not significant.) FIG. 36B: Cynomologus monkeys were treated in three parts as indicated. Human IL-4 (25 μg/kg) was injected subcutaneously twice daily for 4 days and human IL-4 Trap (8 mg/ml) and vehicle were given intravenously daily for 5 days, beginning 1 day prior to human IL-4 administration. Whole blood was collected daily for flow cytometry analysis for CD16. Results were expressed as mean +/−SEM; n=4. (ANOVA p<0.042; Tukey-Kramer: Part 2 vs. Part 1, p<0.05; Part 2 vs. Part 3 and Part 1 vs. Part 3, not significant.)
FIG. 37: Murine IL-4 Trap partially prevented IL-4-mediated IgE increase in mice. BALB/C mice injected with anti-mouse IgD (100 μl/mouse, s.c.) were randomly divided into 3 groups, each received (on days 3–5) either vehicle, murine IL-4 Trap (1 mg/kg, s.c.), or a monoclonal antibody to mouse IL-4 (1 mg/kg, s.c.). Sera were collected at various time points and assayed for IgE levels. Results were expressed as mean+/−SEM (n=5 per group). (ANOVA p=0.0002; Tukey-Kramer: vehicle vs. IL-4 Trap, p<0.01; vehicle vs. IL-4 antibody, p<0.001; IL-4 Trap vs. IL-4 antibody, not significant).
FIGS. 38A–38H (SEQ ID NOS: 33 and 34): Nucleotide (SEQ ID NO: 33) and deduced amino acid (SEQ ID NO: 34) sequence of IL-4/IL-13 Trap 933.
FIGS. 39A–39G (SEQ ID NOS: 39 and 40): Nucleotide (SEQ ID NO: 39) and deduced amino acid (SEQ ID NO: 40) sequence of IL-4/IL-13 Trap 943.
FIGS. 40A–40I (SEQ ID NOS: 37 and 38): Nucleotide (SEQ ID NO: 37) and deduced amino acid (SEQ ID NO: 38) sequence of IL-4/IL-13 Trap 1126.
FIGS. 41A–41P (SEQ ID NOS: 35 and 36): Nucleotide (SEQ ID NO: 35) and deduced amino acid (SEQ ID NO: 36) sequence of IL-4/IL-13 Trap 1128.
FIGS. 42A–42I (SEQ ID NOS: 41 and 42): Nucleotide (SEQ ID NO: 41) and deduced amino acid (SEQ ID NO: 42) sequence of IL-4/IL-13 Trap 1130.
FIGS. 43A–43P (SEQ ID NOS: 43 and 44): Nucleotide (SEQ ID NO: 43) and deduced amino acid (SEQ ID NO: 44) sequence of IL-4/IL-13 Trap 1132.
FIGS. 44A–44I (SEQ ID NOS: 45 and 46): Nucleotide (SEQ ID NO: 45) and deduced amino acid (SEQ ID NO: 46) sequence of IL-4/IL-13 Trap 1199.
FIGS. 45A–45I (SEQ ID NOS: 47 and 48): Nucleotide (SEQ ID NO: 47) and deduced amino acid (SEQ ID NO: 48) sequence of IL-4/IL-13 Trap 1244.
FIGS. 46A–46I (SEQ ID NOS: 49 and 50): Nucleotide and deduced amino acid sequence of IL-4/IL-13 Trap 1245.
FIGS. 47A–47I (SEQ ID NOS: 51 and 52): Nucleotide (SEQ ID NO: 51) and deduced amino acid (SEQ ID NO: 52) sequence of IL-4/IL-13 Trap 1246.
FIG. 48: The IL-4/IL-13 Trap 1132 can block IL-13 more potently than the IL-4/IL-13 Trap 943. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (E. coli; Preprotech) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for  ̃3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. IL-4/IL-13 Trap 1132 exhibits an IC50 of 64 pM as compared to 184 pM for Trap 943.
FIG. 49: The IL-4/IL-13 Trap 1132 can block IL-4 more potently than the IL-4/IL-13 Trap 943. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 40 pM recombinant human IL-4 (E. coli; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for  ̃3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. IL-4/IL-13 Trap 1132 exhibits an IC50 of 95 pM as compared to 222 pM for Trap 943.
FIG. 50: IL-4/IL-13 Trap 1132 displays a higher affinity for Applicants' rhIL13. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 Applicants' own material (CHO) or Pharmingen (E. coli) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for  ̃3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. IL-4/IL-13 Trap 1132 has an IC50 of 16 pM which indicates a Kd of  ̃9 pM.
FIG. 51: IL-4/IL-13 Trap 1132 can block hIL13 more potently than IL-4/IL-13 Trap 943 with Applicants' rhIL13. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (CHO; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for  ̃3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. IL-4/IL-13 Trap 1132 has an IC50 of 17 pM as compared to 33 pM for 943.
FIGS. 52A–52H (SEQ ID NOS: 53 and 54): The nucleotide (SEQ ID NO: 53) and deduced amino acid (SEQ ID NO: 54) sequence of IL-4/IL-13 Trap 1244-B.
FIGS. 53A–53I (SEQ ID NOS: 55 and 56): The nucleotide (SEQ ID NO: 55) and deduced amino acid (SEQ ID NO: 56) sequence of IL-4/IL-13 Trap 1245-B.
FIGS. 54A–54H (SEQ ID NOS: 57 and 58): The nucleotide (SEQ ID NO: 57) and deduced amino acid (SEQ ID NO: 58) sequence of IL-4/IL-13 Trap 1246-B.
FIGS. 55A–55H (SEQ ID NOS: 59 and 60): The nucleotide (SEQ ID NO: 59) and deduced amino acid (SEQ ID NO: 60) sequence of IL-4/IL-13 Trap 1268.
FIG. 56: IL-4/IL-13 Trap 1132, IL-4/IL-13 Trap 1199 and IL-4/IL-13 Trap 1268 are equally potent in blocking IL13. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 and varying concentrations of IL-4/IL-13 Trap 1132, 1199 or 1268 for  ̃3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. Relative cell proliferation as a percentage of the proliferation of cells in the absence of IL-4/IL-13 Trap is plotted on the y-axis. The IL-4/IL-13 Traps 1132, 1199 and 1268 all block IL-13 with the same potency, indicating that the isotype of the Fc portion does not affect the ability of IL-4/IL-13 Trap to block IL-13 in vitro.



DETAILED DESCRIPTION OF THE INVENTION
The present invention provides an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex comprising:

    
    
        a) a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the specificity determining component of the cytokine's receptor;
        b) a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the signal transducing component of the cytokine's receptor; and
        c) a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component.
    
    


By “cytokine binding portion” what is meant is the minimal portion of the extracellular domain necessary to bind the cytokine. It is accepted by those of skill in the art that a defining characteristic of a cytokine receptor is the presence of the two fibronectin-like domains that contain canonical cysteines and of the WSXWS box (Bazan, J. F., 1990, PNAS 87: 6934–6938). Sequences encoding the extracellular domains of the binding component of the cytokine's receptor and of the signal transducing component of the cytokine's receptor may also be used to create the fusion polypeptide of the invention. Similarly, longer sequences encoding larger portions of the components of the cytokine's receptor may be used. However, it is contemplated that fragments smaller than the extracellular domain will function to bind the cytokine and therefore, the invention contemplates fusion polypeptides comprising the minimal portion of the extracellular domain necessary to bind the cytokine as the cytokine binding portion.
The invention comprises a “specificity determining component” of a cytokine's receptor and a “signal transducing component” of the cytokine's receptor. Regardless of the nomenclature used to designate a particular component or subunit of a cytokine receptor, one skilled in the art would recognize which component or subunit of a receptor is responsible for determining the cellular target of the cytokine, and thus would know which component constitutes the “specificity determining component.”
Similarly, regardless of the nomenclature used, one of skill in the art would know which component or subunit of a receptor would constitute the “signal transducing component.” As used herein, the “signal transducing component” is a component of the native receptor which is not the specificity determining component and which does not bind or weakly binds the cytokine in the absence of the specificity determining component. In the native receptor, the “signal transducing component” may participate in signaling.
For example, while some cytokine receptors have components designated α and β, the IL-4 receptor has a signal transducing component referred to as IL-2Rγ. However, regardless of what name is associated with that component, one skilled in the art would know which component of the IL-4 receptor is the signal transducing component. Thus to practice the present invention and create a high affinity Trap for IL-4, one of skill in the art would create an isolated nucleic acid comprising a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the specificity determining component of the IL-4 receptor (IL-4Rα); a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the signal transducing component of the IL-4 receptor (IL-2Rγ); and a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component (for example, an Fc domain of IgG) to create a high affinity Trap for IL-4.
Some further examples of the receptor components that may be used to prepare cytokine antagonists according to the invention are set forth in Table 1. The Table 1 sets forth, by way of example but not by way of limitation, some of the varied nomenclature used in the scientific literature to describe those components which function as specificity determining components and those which function as signal transducing components of certain cytokine receptors.










Exhibit A









Cytokine
Specificity determining Component
Signal transducing Component





Interleukin-1 (IL-1)
Type I IL-1R(ref. 8)
IL-1R AcP(refs. 8, 11)



Type II IL-1R(ref. 8)



IL-1RI(ref. 11)



IL-1RII(ref. 11)


Interleukin-2 (IL-2)
α-subunit(ref. 2)
β-chain(ref. 3)



α-chain(ref. 3)
β-subunit(ref. 2)



IL2Rα(ref. 1)
γ-chain(ref. 3)




IL-2Rβ(refs. 1, 10)




IL-2Rγ(refs. 1, 10)


Interleukin-3 (IL-3)
IL-3Rα(ref. 1)
βc(ref. 1)



α-subunit(ref. 2)
β-subunit(ref. 2)



α-receptor component(ref. 5)
β-chain(ref. 3)




β-receptor component(ref. 5)


Interleukin-4 (IL-4)
IL-4R(ref. 1)
γ-chain(ref. 3)




IL-2Rγ(ref. 1)


Interleukin-5 (IL-5)
IL-5Rα(ref. 1)
βc(ref. 1)



α-subunit(ref. 2)
β-subunit(ref. 2)



α-receptor compnent(ref. 5)
β-chain(ref. 3)




β-receptor component(ref. 5)


Granulocyte macro-
α-receptor component(ref. 5)
β-receptor component(ref. 5)


page-colony stimulating
α-subunit(ref. 2)
β-subunit(ref. 2)


factor (GM-SCF)
GMRα(refs. 1, 2)
β-chain(ref. 3)




βc(ref. 1)




GMRβ(refs. 1, 2)


Leukemia inhibitory fact-
LIFBP(ref. 1)
gp130(refs. 1, 3)


or (LIF)
α-receptor component(ref. 5)
β-receptor component(ref. 5)


Interleukin-11 (IL-11)
α-chain(ref. 4)
gp130(ref. 4)



NR1(ref. 4)


Interleukin-15 (IL-15)
IL-15Rα(ref. 10)
IL-2Rβ(ref. 10)




IL-2Rγ(ref. 10)


Interferon-γ (IFNγ)
IFN-γR(ref. 7)
AF-1(ref. 7)



IFN-γR1(ref. 7)
IFN-γR2(ref. 7)


TGFβ
Type II(refs. 6, 9)
Type I(refs. 6, 9)









Only a few of the multitude of references are cited in Table 1, and they are set forth as follows:

    1. Sato and Miyajima, Current Opinions in Cell Biology 6: 174–179 (1994)—See page 176, lines 9–16;
    2. Miyajima, et al., Annual Review of Immunology 10: 295–331 (1992)—See page 295, line 4 to page 296, line 1; page 305, last paragraph;
    3. Kondo, et al, Science 262: 1874–1877 (1993)—See page 1874, cols. 1 & 2;
    4. Hilton, et al, EMBO Journal 13: 4765–4775 (1994)—See page 4766, col. 1, lines 20 24;
    5. Stahl and Yancopoulos, Cell 74: 587–590 (1993)—See page 587, column 2, lines 15–22;
    6. Bassing, et al, Journal of Biological Chemistry 269: 14861–14864 (1994)—See page 14861, col. 2, lines 1–9 and 21–28;
    7. Kotenko, et al, Journal of Biological Science 270: 20915–20921 (1995)—See page 20915, lines 1–5 of the abstract;
    8. Greenfeder, et al., Journal of Biological Chemistry 270: 13757–13765 (1995)—See page 13757, col. 1, line 6 to col. 2, line 3 and col. 2, lines 10–12; page 13764, col. 2, last 3 lines and page 13765, col. 1, lines 1–7;
    9. Lebrun and Vale, Molecular Cell Biology 17: 1682–1691 (1997)—See page 1682, Abstract lines 2–6;
    10. Kennedy and Park, Journal of Clinical Immunology 16: 134–143 (1996)—See page 134, lines 1–7 of the abstract; page 136, col 2., lines 1–5;
    11. Wesche, et al., Journal of Biological Chemistry 272: 7727–7731 (1997) See page 7731, lines 20–26.


Kotenko, et al. recently identified the IL-10R2 (IL-10Rβ) chain which is reported to serve as an accessory chain that is essential for the active IL-10 receptor complex and for initiating IL-10 induced signal transduction events (S. V. Kotenko, et al., The EMBO Journal, 1997, Vol. 16: 5894–5903). Additional cytokines and their receptors are described in Appendix II, page A:9 of Immunobiology, The Immune System In Health and Disease, 2nd Edition, by Charles A. Janeway, Jr. and Paul Travers, published by Current Biology Ltd./Garland Publishing Inc., copyright 1996.
In preparing the nucleic acid sequence encoding the fusion polypeptide of the invention, the first, second, and third components of the fusion polypeptide are encoded in a single strand of nucleotides which, when expressed by a host vector system, produces a monomeric species of the fusion polypeptide. The monomers thus expressed then multimerize due to the interactions between the multimerizing components (the third fusion polypeptide components). Producing the fusion polypeptides in this manner avoids the need for purification of heterodimeric mixtures that would result if the first and second components were produced as separate molecules and then multimerized. For example, U.S. Pat. No. 5,470,952 issued Nov. 28, 1995 describes the production of heterodimeric proteins that function as CNTF or IL-6 antagonists. The heterodimers are purified from cell lines cotransfected with the appropriate alpha (α) and beta (β) components. Heterodimers are then separated from homodimers using methods such as passive elution from preparative, nondenaturing polyacrylamide gels or by using high pressure cation exchange chromatography. The need for this purification step is avoided by the methods of the present invention.
In addition, PCT International Application WO 96/11213 published Apr. 18, 1996 entitled Dimeric IL-4 Inhibitors states that the applicant has prepared homodimers in which two IL-4 receptors are bound by a polymeric spacer and has prepared heterodimers in which an IL-4 receptor is linked by a polymeric spacer to an IL-2 receptor gamma chain. The polymeric spacer described is polyethylene glycol (PEG). The two receptor components, IL-4R and IL-2Rgamma are separately expressed and purified. Pegylated homodimers and heterodimers are then produced by joining the components together using bi-functional PEG reagents. It is an advantage of the present invention that it avoids the need for such time consuming and costly purification and pegylation steps.
In one embodiment of the invention, the nucleotide sequence encoding the first component is upstream of the nucleotide sequence encoding the second component. In another embodiment of the invention, the nucleotide sequence encoding the first component is downstream of the nucleotide sequence encoding the second component. Further embodiments of the invention may be prepared in which the order of the first, second and third fusion polypeptide components are rearranged. For example, if the nucleotide sequence encoding the first component is designated 1, the nucleotide sequence encoding the second component is designated 2, and the nucleotide sequence of the third component is designated 3, then the order of the components in the isolated nucleic acid of the invention as read from 5′ to 3′ may be any of the following six combinations: 1,2,3; 1,3,2; 2,1,3; 2,3,1; 3,1,2; or 3,2,1.
In further embodiments of the invention, the cytokine bound by the fusion polypeptide may be a member of the hematopoietin family of cytokines selected from the group consisting of interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-9, interleukin-11, interleukin-13, interleukin-15, granulocyte macrophage colony stimulating factor, oncostatin M, leukemia inhibitory factor, and cardiotrophin-1.
In additional embodiments of the invention, the cytokine bound by the fusion polypeptide may be a member of the interferon family of cytokines selected from the group consisting of IFN-gamma, IFN-alpha, and IFN-beta.
In additional embodiments of the invention, the cytokine bound by the fusion polypeptide may be a member of the immunoglobulin superfamily of cytokines selected from the group consisting of B7.1 (CD80) and B7.2 (B70).
In still further embodiments of the invention, the cytokine bound by the fusion polypeptide may be a member of the TNF family of cytokines selected from the group consisting of TNF-alpha, TNF-beta, LT-beta, CD40 ligand, Fas ligand, CD 27 ligand, CD 30 ligand, and 4-1BBL.
In additional embodiments of the invention, the cytokine bound by the fusion polypeptide may be a cytokine selected from the group consisting of interleukin-1, interleukin-10, interleukin-12, interleukin-14, interleukin-18, and MIF.
Because specificity determination and signal transduction occurs by a similar mechanism in the TGF-β/BMP family of cytokines (See D. Kingsley, Genes & Development, 1994, 8: 133–146; J. Wrana, Miner Electrolyte Metab, 24: 120–130 (1998); R. Derynck and X. Feng, Biochimica et Biophysica Acta 1333 (1997) F105-F150; and J. Massague and F. Weis-Garcia, “Serine/threonine Kinase Receptors: Mediators of Transforming Growth Factor Beta Family Signals” In Cancer Surveys, Vol. 27: Cell Signaling, 1996, Imperial Cancer Research Fund) the present invention may be used to produce high affinity antagonists for cytokines that are members of the TGF-β/BMP family.
Therefore, in additional embodiments of the invention, the cytokine bound by the fusion polypeptide may be a member of the TGF-β/BMP family selected from the group consisting of TGF-β1, TGF-β2, TGF-β3, BMP-2, BMP-3a, BMP-3b, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8a, BMP-8b, BMP-9, BMP-10, BMP-11, BMP-15, BMP-16, endometrial bleeding associated factor (EBAF), growth differentiation factor-1 (GDF-1), GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-12, GDF-14, mullerian inhibiting substance (MIS), activin-1, activin-2, activin-3, activin-4, and activin-5.
In alternative embodiments of the invention, the specificity determining component, the signal transducing component, or both, may be substituted for by a single chain Fv. A single chain Fv (scFv) is a truncated Fab having only the V region of a heavy chain linked by a stretch of synthetic peptide to a V region of a light chain. See, for example, U.S. Pat. Nos. 5,565,332; 5,733,743; 5,837,242; 5,858,657; and 5,871,907 assigned to Cambridge Antibody Technology Limited incorporated by reference herein. Thus the present invention contemplates, for example, an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex comprising a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the specificity determining component of the cytokine's receptor; a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence of an scFv capable of binding the cytokine at a site different from the site at which the cytokine binding portion of the extracellular domain of the specificity determining component of the cytokine's receptor binds; and a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component. Alternatively, the specificity determining component may be substituted for by a scFv that binds to a site on the cytokine different from the site at which the signal transducing component binds. Thus the invention contemplates an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex comprising a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of a scFv that binds to a site on the cytokine different from the site at which the cytokine binding portion of the extracellular domain of the signal transducing component of the cytokine's receptor binds; a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence of the cytokine binding portion of the extracellular domain of the signal transducing component of the cytokine's receptor; and a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component.
In another embodiment, the invention contemplates an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex comprising a nucleotide sequence encoding a first fusion polypeptide component comprising the amino acid sequence of a first scFv that binds to a site on the cytokine; a nucleotide sequence encoding a second fusion polypeptide component comprising the amino acid sequence a second scFv that binds to a site on the cytokine different from the site at which the first scFv binds; and a nucleotide sequence encoding a third fusion polypeptide component comprising the amino acid sequence of a multimerizing component.
In all of the above described embodiments comprising scFv's, the invention also contemplates embodiments in which the nucleotide sequence encoding the first component is upstream of the nucleotide sequence encoding the second component; embodiments in which the nucleotide sequence encoding the first component is downstream of the nucleotide sequence encoding the second component; and further embodiments of the invention in which the order of the first, second and third fusion polypeptide components is rearranged. For example, if the nucleotide sequence encoding the first component is designated 1, the nucleotide sequence encoding the second component is designated 2, and the nucleotide sequence of the third component is designated 3, then the order of the components in the isolated nucleic acid of the invention as read from 5′ to 3′ may be any of the following six combinations: 1,2,3; 1,3,2; 2,1,3; 2,3,1; 3,1,2; or 3,2,1.
In preferred embodiments of the invention, the multimerizing component comprises an immunoglobulin derived domain. More specifically, the immunoglobulin derived domain may be selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG. In another embodiment, the multimerizing component may be an Fc domain from which the first five amino acids (including a cysteine) have been removed to produce a multimerizing component referred to as Fc(ΔC1). Alternatively, the multimerizing component may be an Fc domain in which a cysteine within the first five amino acids has been substituted for by another amino acid such as, for example, serine or alanine.
The present invention also provides for fusion polypeptides encoded by the isolated nucleic acid molecules of the invention. Preferably, the fusion polypeptides are in multimeric form, due to the function of the third multimerizing component. In a preferred embodiment, the multimer is a dimer. Suitable multimerizing components are sequences encoding an immunoglobulin heavy chain hinge region (Takahashi et al., 1982, Cell 29:671–679); immunoglobulin gene sequences, and portions thereof. In a preferred embodiment of the invention, immunoglobulin gene sequences, especially one encoding the Fc domain, are used to encode the third multimerizing component.
The present invention also contemplates a vector which comprises the nucleic acid molecule of the invention as described herein.
Also provided is an expression vector comprising a nucleic acid molecule of the invention as described herein, wherein the nucleic acid molecule is operatively linked to an expression control sequence. Also provided is a host-vector system for the production of a fusion polypeptide which comprises the expression vector of the invention which has been introduced into a host cell suitable for expression of the fusion polypeptide. The suitable host cell may be a bacterial cell such as E. coli, a yeast cell, such as Pichia pastoris, an insect cell, such as Spodoptera frugiperda, or a mammalian cell, such as a COS, CHO, 293, BHK or NS0 cell.
The present invention also provides for methods of producing the fusion polypeptides of the invention by growing cells of the host-vector systems described herein, under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.
The present invention provides novel antagonists which are based on receptor components that are shared by cytokines such as the CNTF family of cytokines.
The invention described herein contemplates the production of antagonists to any cytokine that utilizes an α specificity determining component which, when combined with the cytokine, binds to a first β signal transducing component to form a nonfunctional intermediate which then binds to a second β signal transducing component causing β-receptor dimerization and consequent signal transduction. According to the invention, the soluble α specificity determining component of the receptor (sRα) and the extracellular domain of the first β signal transducing component of the cytokine receptor (β1) are combined to form heterodimers (sRα:βl) that act as antagonists to the cytokine by binding the cytokine to form a nonfunctional complex.
As described in Example 1, CNTF and IL-6 share the β1 receptor component gp130. The fact that CNTF forms an intermediate with CNTFRα and gp130 can be demonstrated (Example 1) in cells lacking LIFRβ, where the complex of CNTF and CNTFRα binds gp130, and prevents homodimerization of gp130 by IL-6 and IL-6Rα, thereby blocking signal transduction. These studies provide the basis for the development of the IL-6 antagonists described herein, as they show that if, in the presence of a ligand, a nonfunctional intermediate complex, consisting of the ligand, its α receptor component and its β1 receptor component, can be formed, it will effectively block the action of the ligand. Other cytokines may use other β1 receptor components, such as LIFRβ, which may also be used to produce antagonists according to the present invention.
Thus for example, in one embodiment of the invention, effective antagonists of IL-6 or CNTF consist of heterodimers of the extracellular domains of the α specificity determining components of their receptors (sIL-6Rα and sCNTFRα, respectively) and the extracellular domain of gp130. The resultant heterodimers, which are referred to hereinafter as sIL-6Rα:β1 and sCNTFRα:β1, respectively, function as high-affinity Traps for IL-6 or CNTF, respectively, thus rendering the cytokine inaccessible to form a signal transducing complex with the native membrane-bound forms of their receptors.
Although soluble ligand binding domains from the extracellular portion of receptors have proven to be somewhat effective as Traps for their ligands and thus act as antagonists [Bargetzi, et al., Cancer Res. 53:4010–4013 (1993);, et al., Proc. Natl. Acad. Sci. USA 89: 8616–8620 (1992); Mohler, et al., J. Immunol. 151: 1548–1561 (1993); Narazaki, et al., Blood 82: 1120–1126 (1993)], the IL-6 and CNTF receptors are unusual in that the α receptor components constitute ligand binding domains that, in concert with their ligands, function effectively in soluble form as receptor agonists [Davis, et al. Science 259:1736–1739 (1993); Taga, et al., Cell 58: 573–581 (1989)]. The sRα:β1 heterodimers prepared according to the present invention provide effective Traps for their ligands, binding these ligands with affinities in the picomolar range (based on binding studies for CNTF to PC12D cells) without creating functional intermediates. The technology described herein may be applied to develop a cytokine Trap for any cytokine that utilizes an α-component that confers specificity, as well as a β component which, when bound to the α-specificity component, has a higher affinity for the cytokine than either component alone. Accordingly, antagonists according to the invention include antagonists of interleukins 1 through 5 [IL-1, Greenfeder, et al. J. Biol. Chem. 270:13757–13765 (1995); Guo, et al. J. Biol. Chem. 270:27562–27568 (1995)], IL-2; [Taniguchi, et al. European Patent Nos. 0386289-A and 0386304-A (1990); Takeshita, et al. Science 257:379–382 (1992)]; IL-3; [Kitamura, et al. Cell 66:1165-1174 (1991)], IL-4; [Idzerda, et al. J. Exp. Med. 171:861–873 (1990)], IL-5; [Taverneir, et al. Cell 66:1175–1184 (1991)], IL-11 [(Cherel, et al. Direct Submission to EMBL/GenBank/DDBJ databases; accession No. Z38102)], interleukin 15 [IL-15; Hemar, et al. J. Cell Biol. 1295:55–64 (1995); Taniguchi, et al. European Patent Nos. 0386289-A and 0386304-A (1990); Takeshita, et al. Science 257:379–382 (1992)], granulocyte-macrophage colony stimulating factor [GM-CSF; Hayashida, et al. Proc. Natl. Acad. Sci. U.S.A. 97:9655–9659 (1990)], LIF, gamma interferon [IFNγ; Aguet, et al. Cell 55:273–280 (1988); Soh, et al. Cell 76:793–802 (1994)], and transforming growth factor beta [TGFβ; Inagaki, et al. Proc. Natl. Acad. Sci. USA 90:5359–5363 (1993)].
The α and β receptor extracellular domains may be prepared using methods known to those skilled in the art. The CNTFRα receptor has been cloned, sequenced and expressed [Davis, et al. (1991) Science 253:59–63 which is incorporated by reference in its entirety herein]. The cloning of LIFRβ and gp130 are described in Gearing et al. in EMBO J. 10:2839–2848 (1991), Hibi, et al. Cell 63:1149–1157 (1990) and in published PCT application WO 93/10151 published May 27, 1993, all of which are incorporated by reference in their entirety herein.
The receptor molecules useful for practicing the present invention may be prepared by cloning and expression in a prokaryotic or eukaryotic expression system. The recombinant receptor gene may be expressed and purified utilizing any number of methods. The gene encoding the factor may be subcloned into a bacterial expression vector, such as for example, but not by way of limitation, pCP110.
The recombinant factors may be purified by any technique which allows for the subsequent formation of a stable, biologically active protein. For example, and not by way of limitation, the factors may be recovered from cells either as soluble proteins or as inclusion bodies, from which they may be extracted quantitatively by 8M guanidinium hydrochloride and dialysis. In order to further purify the factors, conventional ion exchange chromatography, hydrophobic interaction chromatography, reverse phase chromatography or gel filtration may be used.
The sRα:β heterodimeric receptors may be engineered using known fusion regions, as described in published PCT application WO 93/10151 published May 27, 1993 entitled “Receptor for Oncostatin M and Leukemia Inhibitory Factor” which describes production of β receptor heterodimers, or they may be prepared by crosslinking of extracellular domains by chemical means. The domains utilized may consist of the entire extracellular domain of the α and β components, or they may consist of mutants or fragments thereof that maintain the ability to form a complex with its ligand and other components in the sRα:β1 complex. For example, as described below in Example 4, IL-6 antagonists have been prepared using gp130 that is lacking its three fibronectin-like domains.
In one embodiment of the invention, the extracellular domains are engineered using leucine zippers. The leucine zipper domains of the human transcription factors c-jun and c-fos have been shown to form stable heterodimers [Busch and Sassone-Corsi, Trends Genetics 6: 36–40 (1990); Gentz, et al., Science 243: 1695–1699 (1989)] with a 1:1 stoichiometry. Although jun-jun homodimers have also been shown to form, they are about 1000-fold less stable than jun-fos heterodimers. Fos-fos homodimers have not been detected.
The leucine zipper domain of either c-jun or c-fos are fused in frame at the C-terminus of the soluble or extracellular domains of the above mentioned receptor components by genetically engineering chimeric genes. The fusions may be direct or they may employ a flexible linker domain, such as the hinge region of human IgG, or polypeptide linkers consisting of small amino acids such as glycine, serine, threonine or alanine, at various lengths and combinations. Additionally, the chimeric proteins may be tagged by His-His-His-His-His-His (His6),[SEQ. ID NO. 1] to allow rapid purification by metal-chelate chromatography, and/or by epitopes to which antibodies are available, to allow for detection on western blots, immunoprecipitation, or activity depletion/blocking in bioassays.
In another embodiment, as described below in Example 3, the srα: β1 heterodimer is prepared using a similar method, but using the Fc-domain of human IgG1 [Aruffo, et al., Cell 67:35–44 (1991)]. In contrast to the latter, formation of heterodimers must be biochemically achieved, as chimeric molecules carrying the Fc-domain will be expressed as disulfide-linked homodimers. Thus, homodimers may be reduced under conditions that favor the disruption of inter-chain disulfides but do not effect intra-chain disulfides. Then monomers with different extracellular portions are mixed in equimolar amounts and oxidized to form a mixture of homo- and heterodimers. The components of this mixture are separated by chromatographic techniques. Alternatively, the formation of this type of heterodimers may be biased by genetically engineering and expressing molecules that consist of the soluble or extracellular portion of the receptor components followed by the Fc-domain of hIgG, followed by either the c-jun or the c-fos leucine zippers described above [Kostelny, et al., J. Immunol. 148: 1547–1553 (1992)]. Since these leucine zippers form predominately heterodimers, they may be used to drive formation of the heterodimers where desired. As for the chimeric proteins described using leucine zippers, these may also be tagged with metal chelates or an epitope. This tagged domain can be used for rapid purification by metal-chelate chromatography, and/or by antibodies, to allow for detection on western blots, immunoprecipitation, or activity depletion/blocking in bioassays.
In additional embodiments, heterodimers may be prepared using other immunoglobulin derived domains that drive the formation of dimers. Such domains include, for example, the heavy chains of IgG (Cγ1 and Cγ4), as well as the constant regions of kappa (κ) and lambda (λ) light chains of human immunoglobulins. The heterodimerization of Cγ with the light chain occurs between the CH1 domain of Cγ and the constant region of the light chain (CL), and is stabilized by covalent linking of the two domains via a single disulfide bridge. Accordingly, as described in Example 4, constructs may be prepared using these immunoglobulin domains. Alternatively, the immunoglobulin domains include domains that may be derived from T cell receptor components which drive dimerization.
In another embodiment of the invention, the sRα:β1 heterodimers are prepared by expression as chimeric molecules utilizing flexible linker loops. A DNA construct encoding the chimeric protein is designed such that it expresses two soluble or extracellular domains fused together in tandem (“head to head”) by a flexible loop. This loop may be entirely artificial (e.g. polyglycine repeats interrupted by serine or threonine at a certain interval) or “borrowed” from naturally occurring proteins (e.g. the hinge region of hIgG). Molecules may be engineered in which the order of the soluble or extracellular domains fused is switched (e.g. sIL6Rα/loop/sgp130 or sgp130/loop/sIL-6Rα) and/or in which the length and composition of the loop is varied, to allow for selection of molecules with desired characteristics.
Alternatively, the heterodimers made according to the present invention may be purified from cell lines cotransfected with the appropriate α and β components. Heterodimers may be separated from homodimers using methods available to those skilled in the art. For example, limited quantities of heterodimers may be recovered by passive elution from preparative, nondenaturing polyacrylamide gels. Alternatively, heterodimers may be purified using high pressure cation exchange chromatography. Excellent purification has been obtained using a Mono S cation exchange column.
In addition to sRα:β1 heterodimers that act as antagonists by binding free CNTF or IL-6, the present invention also contemplates the use of engineered, mutated versions of IL-6 with novel properties that allow it to bind to IL-6Rα and a single gp130 molecule, but fail to engage the second gp130 to complete β component homodimerization, and thus act as an effective IL-6 antagonist on any IL-6 responsive cell. Our model for the structure of the IL-6 and CNTF receptor complexes indicates that these cytokines have distinct sites for binding the α, β1, and β2 receptor components [Stahl and Yancopoulos, Cell 74: 587–590 (1993)]. Mutations of critical amino acid residues comprising each of these sites gives rise to novel molecules which have the desired antagonistic properties. Ablation of the β1 site would give a molecule which could still bind to the α receptor component but not the β1 component, and thereby comprise an antagonist with nanomolar affinity. Mutations of critical amino acid residues comprising the β2 site of IL-6 (IL-6β2−) would give a molecule that would bind to IL-6Rα and the first gp130 monomer, but fail to engage the second gp130 and thus be functionally inactive. Similarly, mutations of the CNTF β2 site would give a molecule (CNTFβ2−1) that would bind CNTFRα and gp130, but fail to engage LIFRβ, thereby antagonizing CNTF action by forming the non-functional β1 intermediate. Based on the binding results described above where CNTF forms the β1 intermediate with high affinity, both CNTFβ2− and IL-6β2− would constitute antagonists with affinity in the range of 10 pM.
A variety of means are used to generate and identify mutations of IL-6 or CNTF that have the desired properties. Random mutagenesis by standard methods of the DNA encoding IL-6 or CNTF may be used, followed by analysis of the collection of products to identify mutated cytokines having the desired novel properties as outlined below. Mutagenesis by genetic engineering has been used extensively in order to elucidate the structural organization of functional domains of recombinant proteins. Several different approaches have been described in the literature for carrying out deletion or substitution mutagenesis. The most successful appear to be alanine scanning mutagenesis [Cunningham and Wells (1989), Science 244: 1081–1085] and homolog-scanning mutagenesis [Cunningham, et al., (1989), Science 243:1330–1336].
Targeted mutagenesis of the IL-6 or CNTF nucleic acid sequences using such methods can be used to generate CNTFβ2- or IL-6β2-candidates. The choice of regions appropriate for targeted mutagenesis is done systematically, or determined from studies whereby panels of monoclonal antibodies against each factor are used to map regions of the cytokine that might be exposed after binding of the cytokine to the α receptor component alone, or to the αβ1 heterodimeric soluble receptors described above. Similarly, chemical modification or limited proteolysis of the cytokine alone or in a complex bound to the α receptor component or the αβ1 heterodimeric soluble receptors described above, followed by analysis of the protected and exposed regions could reveal potential β2 binding sites.
Assays for identifying CNTF or IL-6 mutants with the desired properties involve the ability to block with high affinity the action of IL-6 or CNTF on appropriately responsive cell lines [Davis, et al., Science 259: 1736–1739 (1993); Murakami, et al., Proc. Natl. Acad. Sci. USA 88: 11349–11353 (1991)]. Such assays include cell proliferation, survival, or DNA synthesis driven by CNTF or IL-6, or the construction of cell lines where binding of factor induces production of reporters such as CAT or β-galactosidase [Savino, et al., Proc. Natl. Acad. Sci. USA 90: 4067–4071 (1993)].
Alternatively, the properties of various mutants may be assessed with a receptor-based assay. One such assay consists of screening mutants for their ability to bind the sRα:β1 receptor heterodimers described above using epitope-tagged [Davis et al., Science 253: 59–63 (1991)] sRα:β1 reagents. Furthermore, one can probe for the presence or absence of the β2 site by assessing whether an epitope-tagged soluble β2 reagent will bind to the cytokine in the presence of the β1 heterodimer. For example, CNTF only binds to LIFRβ (the β2 component) in the presence of both CNTFRα and gp130 [Davis, et al. Science 260: 1805–1808 (1993); Stahl, et al. J. Biol. Chem. 268: 7628–7631 (1993)]. Thus a soluble LIFRβ reagent would only bind to CNTF in the presence of the soluble sRα,β1 dimer sCNTFRα:β1. For IL-6, the sRα:β1 reagent would be IL-6Rα:β1, and the probe for the β2 site would be epitope-tagged sgp130. Thus β2− mutants of CNTF would be identified as those that bound the sRα:β1 reagent, demonstrating that the α and β1 site of the cytokine were intact, yet failed to bind the β2 reagent.
In addition, the present invention provides for methods of detecting or measuring the activity of potential β2− mutants by measuring the phosphorylation of a β-receptor component or a signal transduction component selected from the group consisting of Jak1, Jak2 and Tyk2 or any other signal transduction component, such as the CLIPs, that are determined to be phosphorylated in response to a member of the CNTF family of cytokines.
A cell that expresses the signal transduction component(s) described herein may either do so naturally or be genetically engineered to do so. For example, Jak1 and Tyk-2-encoding nucleic acid sequences obtained as described in Velazquez, et al., Cell, Vol. 70:313–322 (1992), may be introduced into a cell by transduction, transfection, microinjection, electroporation, via a transgenic animal, etc., using any known method known in the art.
According to the invention, cells are exposed to a potential antagonist and the tyrosine phosphorylation of either the β-component(s) or the signal transduction component(s) are compared to the tyrosine phosphorylation of the same component(s) in the absence of the potential antagonist. In another embodiment of the invention, the tyrosine phosphorylation that results from contacting the above cells with the potential antagonist is compared to the tyrosine phosphorylation of the same cells exposed to the parental CNTF family member. In such assays, the cell must either express the extracellular receptor (α-component) or the cells may be exposed to the test agent in the presence of the soluble receptor component. Thus, for example, in an assay system designed to identify agonists or antagonists of CNTF, the cell may express the α-component CNTFRα, the β-components gp130 and LIFRβ and a signal transducing component such as Jak1. The cell is exposed to test agents, and the tyrosine phosphorylation of either the β-components or the signal transducing component is compared to the phosphorylation pattern produced in the presence of CNTF. Alternatively, the tyrosine phosphorylation which results from exposure to a test agent is compared to the phosphorylation which occurs in the absence of the test agent. Alternatively, an assay system, for example, for IL-6 may involve exposing a cell that expresses the β-component gp130 and a signal transducing protein such as Jak1, Jak2 or Tyk2 to a test agent in conjunction with the soluble IL-6 receptor.
In another embodiment of the invention the above approaches are used to develop a method for screening for small molecule antagonists that act at various steps in the process of ligand binding, receptor complex formation, and subsequent signal transduction. Molecules that potentially interfere with ligand-receptor interactions are screened by assessing interference of complex formation between the soluble receptors and ligand as described above. Alternatively, cell-based assays in which IL-6 or CNTF induce response of a reporter gene are screened against libraries of small molecules or natural products to identify potential antagonists. Those molecules showing antagonist activity are rescreened on cell-based assays responding to other factors (such as GM-CSF or factors like Neurotrophin-3 that activate receptor tyrosine kinases) to evaluate their specificity against the CNTF/IL-6/OSM/LIF family of factors. Such cell-based screens are used to identify antagonists that inhibit any of numerous targets in the signal transduction process.
In one such assay system, the specific target for antagonists is the interaction of the Jak/Tyk family of kinases [Firmbach-Kraft, Oncogene 5: 1329–1336 (1990); Wilks, et al., Mol. Cell. Biol. 11:2057–2065 (1991)] with the receptor β subunits. As described above, LIFRβ and gp130 preassociate with members of the Jak/Tyk family of cytoplasmic protein tyrosine kinases, which become activated in response to ligand-induced β component dimerization Stahl, et al. Science 263:92–95 (1993). Thus small molecules that could enter the cell cytoplasm and disrupt the interaction between the β component and the Jak/Tyk kinase could potentially block all subsequent intracellular signaling. Such activity could be screened with an in vitro scheme that assessed the ability of small molecules to block the interaction between the relevant binding domains of purified β component and Jak/Tyk kinase. Alternatively, one could easily screen for molecules that could inhibit a yeast-based assay of β component binding to Jak/Tyk kinases using the two-hybrid interaction system [Chien, et al., Proc. Natl. Acad. Sci. 88: 9578–9582 (1991)]. In such a system, the interaction between two proteins (β component and Jak/Tyk kinase or relevant domains thereof in this example) induces production of a convenient marker such as β-galactosidase. Collections of small molecules are tested for their ability to disrupt the desired interaction without inhibiting the interaction between two control proteins. The advantage of this screen would be the requirement that the test compounds enter the cell before inhibiting the interaction between the β component and the Jak/Tyk kinase.
The CNTF family antagonists described herein either bind to, or compete with the cytokines CNTF and IL-6. Accordingly, they are useful for treating diseases or disorders mediated by CNTF or IL-6. For example, therapeutic uses of IL-6 antagonists would include the following:

    
    
        1) In osteoporosis, which can be exacerbated by lowering of estrogen levels in post-menopausal women or through ovariectomy, IL-6 appears to be a critical mediator of osteoclastogenesis, leading to bone resorption [Horowitz, Science 260: 626–627 (1993); Jilka, et al., Science 257: 88–91 (1992)]. Importantly, IL-6 only appears to play a major role in the estrogen-depleted state, and apparently is minimally involved in normal bone maintenance. Consistent with this, experimental evidence indicates that function-blocking antibodies to IL-6 can reduce the number of osteoclasts [Jilka, et al. Science 257: 88–91 (1992)]. While estrogen replacement therapy is also used, there appear to be side effects that may include increased risk of endometrial and breast cancer. Thus, IL-6 antagonists as described herein would be more specific to reduce osteoclastogenesis to normal levels.
        2) IL-6 appears to be directly involved in multiple myeloma by acting in either an autocrine or paracrine fashion to promote tumor formation [van Oers, et al., Ann Hematol. 66: 219–223 (1993)]. Furthermore, the elevated IL-6 levels create undesirable secondary effects such as bone resorption, hypercalcemia, and cachexia; in limited studies function-blocking antibodies to IL-6 or IL-6Ra have some efficacy [Klein, et al., Blood 78: 1198–1204 (1991); Suzuki, et al., Eur. J. Immunol. 22:1989–1993 (1992)]. Therefore, IL-6 antagonists as described herein would be beneficial for both the secondary effects as well as for inhibiting tumor growth.
        3) IL-6 may be a mediator of tumor necrosis factor (TNF) that leads to cachexia associated with AIDS and cancer [Strassmann, et al., J. Clin. Invest. 89: 1681–1684 (1992)], perhaps by reducing lipoprotein lipase activity in adipose tissue [Greenberg, et al., Cancer Research 52: 4113–4116 (1992)].
    
    


Accordingly, antagonists described herein would be useful in alleviating or reducing cachexia in such patients.
Effective doses useful for treating these or other CNTF family related diseases or disorders may be determined using methods known to one skilled in the art [see, for example, Fingl, et al., The Pharmacological Basis of Therapeutics, Goodman and Gilman, eds. Macmillan Publishing Co., New York, pp. 1–46 ((1975)]. Pharmaceutical compositions for use according to the invention include the antagonists described above in a pharmacologically acceptable liquid, solid or semi-solid carrier, linked to a carrier or targeting molecule (e.g., antibody, hormone, growth factor, etc.) and/or incorporated into liposomes, microcapsules, and controlled release preparation (including antagonist expressing cells) prior to administration in vivo. For example, the pharmaceutical composition may comprise one or more of the antagonists in an aqueous solution, such as sterile water, saline, phosphate buffer or dextrose solution. Alternatively, the active agents may be comprised in a solid (e.g. wax) or semi-solid (e.g. gelatinous) formulation that may be implanted into a patient in need of such treatment. The administration route may be any mode of administration known in the art, including but not limited to intravenously, intrathecally, subcutaneously, by injection into involved tissue, intraarterially, intranasally, orally, or via an implanted device.
Administration may result in the distribution of the active agent of the invention throughout the body or in a localized area. For example, in some conditions which involve distant regions of the nervous system, intravenous or intrathecal administration of agent may be desirable. In some situations, an implant containing active agent may be placed in or near the lesioned area. Suitable implants include, but are not limited to, gelfoam, wax, or microparticle-based implants.
EXAMPLES
Example 1
CNTF Competes with IL-6 for Binding to gp130
Materials and Methods
Materials. A clone of PC12 cells that respond to IL-6 (PC12D) was obtained from DNAX. Rat CNTF was prepared as described [Masiakowski, et al., J. Neurochem. 57:1003–10012 (1991)]. IL-6 and sIL-6Rα were purchased from R & D Systems. Antisera was raised in rabbits against a peptide derived from a region near the C-terminus of gp130 (sequence: CGTEGQVERFETVGME) [SEQ. ID. NO. 2] by the method described (Stahl, et al. J. Biol. Chem. 268:7628–7631 (1993). Anti-phosphotyrosine monoclonal 4G10 was purchased from UBI, and reagents for ECL from Amersham.
Signal Transduction Assays. Plates (10 cm) of PC12D were starved in serum-free medium (RPMI 1640+glutamine) for 1 hour, then incubated with IL-6 (50 ng/mL)+sIL-6R (1 mg/mL) in the presence or absence of added rat CNTF at the indicated concentrations for 5 minutes at 37° C. Samples were then subjected to anti-gp130 immunoprecipitation, SDS PAGE, and anti-phosphotyrosine immunoblotting as described (Stahl, et al. J. Biol. Chem. 268:7628–7631 (1993).
Results
The ability of CNTF to block IL-6 responses was measured using a PC12 cell line (called PC12D) that expresses IL-6Rα, gp130, and CNTFRα, but not LIFRα. As one would predict, these cells respond to IL-6, but not to CNTF (FIG. 2) since LIFRβ is a required component for CNTF signal transduction [Davis, et al., Science 260: 59–63 (1993)]. In accordance with results on other cell lines [Ip, et al., Cell 69: 1121–1132 (1992)], PC12D cells give tyrosine phosphorylation of gp130 (as well as a variety of other proteins called CLIPs) in response to 2 nM IL-6 (FIG. 2). Addition of recombinant soluble IL-6Rα (sIL-6Rα) enhances the level of gp130 tyrosine phosphorylation, as has been reported in some other systems [(Taga, et al., Cell 58: 573–581 (1989)]. However, addition of 2 nM CNTF simultaneously with IL-6 severely diminishes the tyrosine phosphorylation of gp130. Although a slight gp130 phosphorylation response remains in the presence of CNTF, IL-6, and sIL-6Rα, it is eliminated if the CNTF concentration is increased fourfold to 8 nM. Thus, in IL-6 responsive cells that contain CNTFRα but no LIFRβ, CNTF is a rather potent antagonist of IL-6 action.
Example 2
Binding of CNTF to the CNTFRα:β
Materials and Methods
Scatchard Analysis of CNTF Binding. 125I-CNTF was prepared and purified as described [Stahl et al. JBC 268: 7628–7631 (1993)]. Saturation binding studies were carried out in PC12 cells, using concentrations of 125I-CNTF ranging from 20 pM to 10 nM. Binding was performed directly on a monolayer of cells. Medium was removed from wells and cells were washed once with assay buffer consisting of phosphate buffered saline (PBS; pH 7.4), 0.1 mM bacitracin, 1 mM PMSF, 1 mg/ml leupeptin, and 1 mg/ml BSA. Cells were incubated in 125I-CNTF for 2 hours at room temperature, followed by 2 quick washes with assay buffer. Cells were lysed with PBS containing 1% SDS and counted in a Packard Gamma Counter at 90–95% efficiency. Non-specific binding was defined by the presence of 100-fold excess of unlabelled CNTF. Specific binding ranged from 70% to 95%.
Results
The equilibrium constant for binding of CNTF to CNTFRα:β1 was estimated from Scatchard analysis of iodinated CNTF binding on PC12D cells (FIG. 3). The data is consistent with a 2 site fit having dissociation constants of 9 pM and 3.4 nM. The low affinity site corresponds to interaction of CNTF with CNTFRα, which has a Kd near 3 nM [(Panayotatos, et al., J. Biol. Chem. 268: 19000–19003 (1993)]. We interpret the high affinity complex as the intermediate containing CNTF, CNTFRα, and gp130. A Ewing sarcoma cell line (EW-1) which does contain CNTFRα, gp130, and LIFRβ, and therefore gives robust tyrosine phosphorylation in response to CNTF, displays a very similar two site fit with dissociation constants of 1 nM and 10. Thus it is apparent that CNTF binds with equally high affinity to a complex containing only CNTFRα and gp130, as it does to a complex which additionally contains LIFRβ, thus demonstrating the feasibility of creating the sRα:β antagonists described herein.
Example 3
Methods of Producing Cytokine Ligand Traps
Virus Stock Production
SF21 insect cells obtained from Spodoptera frugiperda were grown at 27° C. in Gibco SF900 II medium to a density of 1×106 cells/mL. The individual virus stock for either GP130-Fc-His6 (FIGS. 4A–4B, [SEQ ID NO: 7]) or IL6Ra-Fc (FIG. 5, [SEQ ID NO: 8]) was added to the bioreactor to a low multiplicity 0.01–0.1 PFU/cell to begin the infection. The infection process was allowed to continue for 5–7 days allowing maximum virus replication without incurring substantial cell lysis. The cell suspension was aseptically aliquoted into sterile centrifuge bottles and the cells removed by centrifugation. The cell-free supernatant was collected in sterile bottles and stored at 4° C. until further use.
The virus titer was determined by plaque assay as described by O'Reilly, Miller and Luckow. The method is carried out in 60 mm tissue-culture dishes which are seeded with 2×106 cells. Serial dilutions of the virus stock are added to the attached cells and the mixture incubated with rocking to allow the virus to adsorb to individual cells. An agar overlay is added and plates incubated for 5–7 days at 27° C. Staining of viable cells with neutral red revealed circular plaques resulting which were counted to give the virus titer.
Coinfection of Cells for Protein Production
Uninfected SF21 Cells were grown in a 60L ABEC bioreactor containing 40L of SF900 11 medium. Temperature was controlled at 27° C. and the dissolved oxygen level was maintained at 50% of saturation by controlling the flowrate of oxygen in the inlet gas stream. When a density of 2×106 cells/mL was reached, the cells were concentrated within the bioreactor to a volume of 20L using a low shear steam sterilizable pump with a tangential flow filtration device with Millipore Prostak 0.65 micron membranes. After concentration fresh sterile growth medium is slowly added to the bioreactor while the filtration system continues to remove the spent growth medium by diafiltration. After two volume exchanges (40L) have been carried out an additional 20L of fresh medium was added to the bioreactor to resuspend the cells to the original volume of 40L. The cell density was determined once again by counting viable cells using a hemacytometer.
The required amount of each virus stock was calculated based on the cell density, virus titer and the desired multiplicity of infection (MOI). Virus stock ratios of 5:1, 5:2, 10:2 and 10:4, IL6Rα-Fc to GP130-Fc-His6 all resulted in production of significant amounts of heterodimer. The ideal virus stock ratio is highly dependent on the ease of purification of the heterodimer from each of the two homodimers. The IL6Rα-Fc homodimer is relatively easy to remove downstream by immobilized metal affinity chromatography. Virus infection ratios have been chosen to minimize the formation of the GP130-Fc-His6 homodimer which is more difficult to clear downstream. The relative amount of GP130-Fc-His6 virus stock chosen for infection has increased with successive batches as the purification method for clearing the resultant homodimer has improved.
The virus stocks were aseptically mixed in a single vessel then transferred to the bioreactor. This results in synchronous infection of the SF21 cells. The infection is allowed to proceed for three to four days, allowing sufficient time for maximal production of the heterodimer protein.
Recovery and Protein A Chromatographic Purification
At the conclusion of the infection phase of the bioreactor process the cells were concentrated in the bioreactor using a 10 ft2 Millipore Prostak filter (0.65 micron) pore size. The cell-free permeate passing through the filter was collected in a clean process vessel. At the conclusion of the filtration operation the pH of permeate stream, containing the protein product, was adjusted to 8.0 with 10N NaOH. The resultant precipitate was removed by forcing the extract through a 0.8 micron depth filter (Sartorious), followed by a 0.2 micron filter. Sufficient 0.5M EDTA stock was added to give a final concentration of 5 mM. The filtered protein solution was loaded onto a 10 cm diameter column containing 100–200 mL of Pharmacia Protein A Sepharose 4 Fast Flow, equilibrated with PBS. Protein A has a very high affinity for the Fc—Fc domain of each of the 3 recombinant protein products, allowing them to bind while other proteins in the cell-free extract flow through the column. After loading the column was washed to baseline with PBS containing an additional 350 mM NaCl. The IgG-Fc tagged proteins were eluted at low pH, either with 0.5M acetic acid or with a decreasing pH gradient of 0.1M citric acid and 0.2M disodium phosphate buffers. Tris base or disodium phosphate was added to the eluted protein to avoid prolonged exposure to low pH conditions.
The pooled protein was diafiltered into PBS or HEPES buffer and derivitized with 1 mM iodoacetamide to protect the exposed sulfhydryl group on the free cysteine near the hinge region of each Fc domain. This prevents disulfide mediated aggregation of proteins. A 6 ft2 Millipore spiral wound ultrafiltration membrane with nominal 30 kiloDalton cutoff was used to perform the buffer exchange. The total protein was determined by UV absorbance at 280 nm using the diafiltration buffer as a blank. The relative amounts of heterodimer and two homodimer proteins were determined by SDS PAGE gel electrophoresis using a 6% Tris-Glycine gel (Novex). Gels were Coomassie-stained then transferred into destain solution overnight. A Shimadzu scanning densitometer was used to determine the relative intensity of the individual protein bands on the SDS PAGE gel. The peak area ratios are used to compute the fraction of heterodimer and each of the homodimers in the column pool fractions.
Immobilized Metal Affinity Chromatographic Purification
The six histidine residues on the C-terminus of the GP130-Fc-His6 fusion protein provides an excellent molecular handle for separation of the heterodimeric IL6 antagonist from the two homodimers. The imidazole group on each of the C-terminal histidines of the GP130-Fc-His6 moiety has a strong binding constant with several divalent metals, including copper, nickel, zinc, cobalt, iron and calcium. Since the IL6Rα-Fc homodimer has no C-terminal histidine residues, it clearly has the lowest affinity. The IL6Rα-Fc-GP130-Fc-His6 heterodimer has a single stand set six histidines giving it greater affinity for the metal, while the GP130-Fc-His6 homodimer has two sets of six histidines each giving it the highest affinity of the three IgG tagged proteins to the metal affinity column. Selective elution of the three proteins with increasing amounts of imidazole in the elution buffer therefore elutes the proteins in the following order:

    
    
        1. IL6Rα-Fc homodimer
        2. IL6Rα-Fc-GP130-Fc-His heterodimer
        3. GP130-Fc-His homodimer
    
    


A 26 mm diameter column containing 100 mL of Pharmacia Chelating Sepharose Fast Flow was saturated with a solution of nickel sulfate until a significant green color is observed in the column eluate. The column is then washed with several column volumes of deionized water, then equilibrated with 50 mM HEPES, 40 mM imidazole, pH 8.0. The binding of imidazole to the immobilized nickel results in a green to blue color change. Imidazole was added to the protein load to a final concentration of 40 mM. Addition of imidazole to the protein load reduces the binding of IL6Rα-Fc homodimer, increasing the surface area available for the remaining two species. After loading, the column was washed with several column volumes of 50 mM HEPES, 80 mM imidazole, pH 8.0 until a steady baseline was reestablished. The heterodimer was selectively eluted with 50 mM HEPES, 150 mM imidazole, pH 8.0 over several column volumes. The protein fractions were pooled and diafiltered into PBS as described in the section above.
Example 4
Alternative Methods of Constructing Ligand Traps
As described above, receptor activation by CNTF, and analogously by IL-6 and IL-11, follows an ordered sequence of binding events (FIG. 6). The cytokine initially binds to its cognate Rα with low affinity (Kd=3 to 10 nM); this is a required step—cells which do not express the cognate Rα do not respond to the cognate cytokine. The cytokine•Rα complex associates with the first signal transducing component, gp130, to form a high affinity complex (Kd in the order of 10 pM for the CNTF•CNTFRα•gp130 complex). This complex does not transduce signal, as it is the dimerization of the signal transducing components that brings about signaling (Stahl and Yancopoulos, J. Neurobiology 25: 1454–1466 (1994); Stahl et al., Science 267:1349–1353 (1995); Davis et al., Science 260:1805–1808 (1993); Stahl et al., Science 263:92–95 (1994); Murakami, et al. Science 260:1808–1810 (1993). At least in the case of IL-6, the cytokine•Rα•signal transducer heterotrimeric complex subsequently associates with another like complex, to form a hexameric complex (FIG. 6) (Ward et al., J. Biol. Chem. 269:23286–23289 (1994). The resulting dimerization of the signal transducers—gp130 in the case of IL-6 (Murakami et al., Science 260:1808–1810 (1993) and IL-11, gp130 and LIFR in the case of CNTF (Davis et al., Science 260:1805–1808 (1993)—brings about signal transduction.
The initial heterodimeric molecules made comprised a soluble Rα-component linked to the extracellular domain of gp130. These molecules were shown to mimic the high affinity cytokine•Rα•gp130 complex and behave as a high affinity antagonist of their cognate cytokine (FIG. 7). To make these molecules, the extracellular domain of gp130 was paired with the extracellular domain of the α-receptor components for IL-6 and CNTF, IL-6Rα and CNTFRα respectively. To link the Rα with the extracellular domain of gp130, the soluble Rα-components and gp130 were fused to the Fc portion of human IgG1 to produce Rα-Fc and gp130-Fc respectively. The Fc domain was chosen primarily but not solely because it naturally forms disulfide-linked dimers. Heterodimeric molecules comprising Rα-Fc•gp130-Fc were expressed, purified and shown to behave as highly potent antagonists of their cognate ligand. Furthermore, these molecules were found to be highly specific for their cognate cytokine since it is the choice of the α-receptor component which specifies which cytokine is bound and trapped (there is no measurable binding of the cytokine to gp130 in the absence of the appropriate Rα).
Here we describe an extension of this technology which allows the engineering of different heteromeric soluble receptor ligand Traps which by virtue of their design may have additional beneficial characteristics such as stability, Fc-receptor-mediated clearance, or reduced effector functions (such as complement fixation). Furthermore, the technology described should prove suitable for the engineering of any heteromeric protein in mammalian or other suitable protein expression systems, including but not limited to heteromeric molecules which employ receptors, ligands, and catalytic components such as enzymes or catalytic antibodies.
Materials And Methods
Genetic Engineering of Heteromeric Immunoglobulin Heavy/Light Chain Soluble Receptor-Based Ligand Traps for IL-6.
The IL-6 Traps described here were engineered using human gp130, human IL-6 α-receptor (IL-6Rα), the constant region of the heavy chains (Cγ) of human IgG1 (Cγ1) (Lewis et al., Journal of Immunology 151:2829–2838 (1993) or IgG4 (Cγ4) with or without a join-region (J), and the constant regions of kappa (κ) and lambda (λ) (Cheung, et al., Journal of Virology 66:6714–6720 (1992) light chains of human immunoglobulin (Ig), also with or without a different j-peptide (j). This design takes advantage of the natural ability of the Cγ domain to heterodimerize with κ or λ light chains. The heterodimerization of Cγ with the light chain occurs between the CH1 domain of Cγ and the constant region of the light chain (CL), and is stabilized by covalent linking of the two domains via a single disulfide bridge. We reasoned that, like the Fc domain of human IgG1, the combination of Cγ with CL could be used to produce disulfide linked heteromeric proteins comprised of the extracellular domain of gp130 on one chain and the extracellular domain of IL-6Rα on the other chain. Like their Fc-based counterparts, such proteins were postulated to be high affinity ligand Traps for IL-6 and as a result to inhibit the interaction of IL-6 with the native receptor on IL-6-responsive cells, thus functioning as IL-6 antagonists. Furthermore, constructs employing the full length Cγ region would, much like antibodies, form homodimers of the Cγ chain, giving rise to antibody-like molecules comprising of two “light chains” and two “heavy chains” (FIG. 8). The potential advantage of this design is that it may more closely mimic the IL-6•IL-6Rα•gp130 complex and may display a higher affinity for the ligand than comparable single heterodimers. An additional design is incorporated by using truncated versions of Cγ, comprised only of the CH1 domain. These will form heterodimeric molecules with receptor-κ fusion proteins, and will thus resemble the Fab fragment of antibodies.
All the soluble receptor-Ig chimeric genes may be engineered in plasmid vectors including, but not limited to, vectors suitable for mammalian expression (COS monkey kidney cells, Chinese Hamster Ovary cells [CHO], and ras-transformed fibroblasts [MG-ras]) and include a Kozak sequence (CGC CGC CAC CAT GGT G) (SEQ ID NO: 3) at the beginning of each chimeric gene for efficient translation. Engineering was performed using standard genetic engineering methodology. Each construct was verified by DNA sequencing, mammalian expression followed by western blotting with suitable antibodies, biophysical assays that determine ligand binding and dissociation, and by growth inhibition assays (XG-1, as described later). Since the domains utilized to engineer these chimeric proteins are flanked by appropriate restriction sites, it is possible to use these domains to engineer other chimeric proteins, including chimeras employing the extracellular domains of the receptors for factors such as IL-1, IL-2, IL-3, IL-4, IL-5, GM-CSF, LIF, IL-11, IL-15, IFNγ, TGFβ, and others. The amino acid coordinates for each component utilized in making the IL-6 Traps are listed below (Note: numbering starts with the initiating methionine as #1; long sequences are listed using the single letter code for the twenty amino acids):
(a) Constructs Employing Human gp130:


    (i) gp130-Cγ1 was engineered by fusing in frame the extracellular domain of gp130 (amino acids 1 to 619) to a Ser-Gly bridge, followed by the 330 amino acids which comprise Cγ1 and a termination codon (FIGS. 9A–9B, SEQ ID NO: 9).
    (ii) gp130-J-Cγ1 was engineered in the same manner as gp130-Cγ1 except that a J-peptide (amino acid sequence: GQGTLVTVSS, SEQ ID NO: 4) was inserted between the Ser-Gly bridge and the sequence of Cγ1 (see FIGS. 9A–9B, SEQ ID NO: 9).
    (iii) gp130Δ3fibro-Cγ1 was engineered by fusing in frame the extracellular domain of gp130 without its three fibronectin-like domains (FIG. 10, SEQ ID NO: 10). The remaining part of this chimeric protein is identical to gp130-Cγ1.
    (iv) gp130-J-CH1 was engineered in a manner identical for that described for gp130-Cγ1, except that in place of the Cγ1 region only the CH1 part of Cγ1 has been used (FIG. 11, SEQ ID NO: 11). The C-terminal domain of this construct includes the part of the hinge that contains the cysteine residue responsible for heterodimerization of the heavy chain of IgG with a light chain. The part of the hinge that contains the two cysteines involved in Cγ1 homodimerization has been deleted along with the CH2 and CH3 domains.
    (v) gp130 -Cγ4 was engineered in a manner identical to that described for gp130-Cγ1, except that Cγ4 was used in place of Cγ1 (FIG. 12, SEQ ID NO: 12). In addition, an RsrII DNA restriction site was engineered at the hinge region of the Cγ4 domain by introducing two silent base mutations. The RsrsII site allows for other desired genetic engineering manipulations, such as the construction of the CH1 equivalent of gp130-Cγ4.
    (vi) gp130-κ was engineered in a manner identical to that described for gp130-Cγ1, except that the constant region of the κ light chain of human Ig was used in place of Cγ1 (FIG. 13, SEQ ID NO: 13).
    (vi) gp130-J-κ was engineered in a manner identical to that described for gp130-J-κ, except that a j-peptide (amino acid sequence: TFGQGTKVEIK, SEQ ID NO: 5) was inserted between the Ser-Gly bridge and the κ-region.
    (viii) gp130-λ was engineered in a manner identical to that described for gp130O-Cγ1, except that the constant region of the λ light chain (Cheung, et al., Journal of Virology 66:6714–6720 (1992) of human Ig was used in place of Cγ1 (FIG. 14, SEQ ID NO: 14).

(b) Constructs employing human IL-6Rα:

    (i) IL6Rα-Cγ1 was engineered by fusing in frame amino acids 1 to 358 of IL-6Rα (Yamasaki et al., Science 241:825–828 (1988), which comprise the extracellular domain of IL-6Rα (FIG. 15, SEQ ID NO: 15), to an Ala-Gly bridge, followed by the 330 amino acids which comprise Cγ1 and a termination codon.
    (ii) IL6Rα-κ was engineered as described for IL6Rα-Cγ1, except that the κ-domain (FIG. 13, SEQ ID NO: 13) utilized for gp130-κ was used in place of Cγ1.
    (iii) IL6Rα-j-κ was engineered as described for IL6Rα-κ except that the j-peptide described for gp130-j-κ was placed between the Ala-Gly bridge and the κ-domain.
    (iv) Three additional constructs, IL6Rα313-Cγ1, IL6Rα313-κ, and IL6Rα313-j-κ, were engineered as using a truncated form of IL-6Rα comprised of amino acids 1 to 313 (FIG. 16, SEQ ID NO: 16). Each of these constructs were made by fusing in frame IL6Rα313 with a Thr-Gly bridge followed by the Cγ1, κ-, and j-κ-domains described above. These constructs were engineered in order to complement the gp130Δ3fibro-derived constructs.

Expression and Purification of Ligand Traps



To produce covalently linked heterodimers of soluble gp130 and soluble IL-6Rα, gp130-Ig chimeric proteins were co-expressed with appropriate IL-6Rα-Ig chimeric proteins in complementing pairs. Co-expression was achieved by co-transfecting the corresponding expression vectors into suitable mammalian cell lines, either stably or transiently. The resulting disulfide-linked heterodimers were purified from conditioned media by several different methods, including but not limited to affinity chromatography on immobilized Protein A or Protein G, ligand-based affinity chromatography, ion exchange, and gel filtration.
An example of the type of methods used for purification of a heavy/light receptor fusion protein is as follows: gp130-Cγ1•IL-6Rα-κ was expressed in COS cells by co-transfecting two different vectors, encoding gp130-Cγ1 and IL-6Rα-κ respectively. Serum-free conditioned media (400 ml) were collected two days post-transfection and Cγ1-bearing proteins were purified by affinity chromatography over a 1 ml Protein A Sepharose (Pharmacia). The material generated in this step was further purified by a second affinity chromatography step over a 1 ml NHS-activated Sepharose (Pharmacia) which was derivatized with recombinant human IL-6, in order to remove gp130-Cγ1 dimer from gp130-Cγ1•IL-6Rα-κ complexes (the gp130-Cγ1 dimer does not bind IL-6). Proteins generated by this method were more than 90% pure, as evidenced by SDS-PAGE followed by silver-staining (FIG. 17). Similar protocols have been employed successfully towards the purification of other heavy/light receptor heterodimers.
Results
Biological Activity of Immunoglobulin Heavy/Light Chain Receptor Fusion Antagonists
The purified ligand Traps were tested for their ability to bind IL-6 in a variety of different assays. For example, the dissociation rate of IL-6 bound to the ligand Trap was measured in parallel with the dissociation rate of IL-6 from the anti-IL-6 monoclonal neutralizing antibody B-E8 [Brochier, et al., Int. J. Immunopharmacology 17:41–48 (1995), and references within]. An example of this type of experiment is shown in FIG. 18. In this experiment 20 pM 125I-IL-6 (1000 μCi/mmol; Amersham) was preincubated with 500 pM of either gp130-Cγ1•IL-6Rα-κ or mAb B-E8 for 20 hours. At this point a 1000-fold excess (20 nM) of “cold” IL-6 was added. Periodically, aliquots of the reaction were removed, the ligand Trap or B-E8 were precipitated with Protein G-Sepharose, and the number of cpm of 125I-IL-6 that remained bound was determined. Clearly, the dissociation rate of human 125I-IL6 from the ligand Trap was very slow—after three days, approximately 75% of the initial counts were still bound to the ligand Trap. In contrast, less than 5% of the counts remained associated with the antibody after three days. This result demonstrates that the dissociation rate of the ligand from these ligand Traps is very slow.
In a different set of experiments the ability of the ligand Traps to multimerize in the presence of ligand was tested. An example of this is shown in FIGS. 19A–19B. IL-6-induced association of gp130-Fc•IL-6Rα-Fc with gp130-CH1•IL-6Rα-κ was determined by testing whether gp130-CH1•IL-6Rα-κ, which does not by itself bind Protein A, could be precipitated by Protein A-Sepharose in the presence of gp130-Fc-IL-6Rα-Fc in an IL-6-depended manner (FIGS. 9A–9B, SEQ ID NO: 9). Precipitation of gp130-CH1•IL-6Rα-κ by Protein A-Sepharose was determined by western blotting with an anti-kappa specific HRP conjugate, which does not detect gp130-Fc•IL-6Rα-Fc. gp130-CH1. IL-6Rα-κ could be precipitated by Protein A-Sepharose only when both gp130-Fc•IL-6Rα-Fc and IL-6 were present. This result conclusively indicates that IL-6 can induce ligand Trap multimerization, and further indicate that the ligand Trap can mimic the hexameric cytokine•Rα•signal transducer complex (FIG. 1). Ligand-induced multimerization may play a significant role in the clearance of cytokine•ligand Trap complexes in vivo.
The biological activity of the different ligand Traps may be further tested in assays which measure ligand-depended cell proliferation. Several cell proliferation assays exist for IL-6 and they employ cell lines such as B9, CESS, or XG-1. An example of this type of assay using the XG-1 cell line is presented below: XG-1 is a cell line derived from a human multiple myeloma (Zhang, et al., Blood 83:3654–3663 (1994). XG-1 depends on exogenously supplied human IL-6 for survival and proliferation. The EC50 of IL-6 for the XG-1 line is approximately 50 pmoles/ml. The ability of several different IL-6 Traps to block IL-6-depended proliferation of XG-1 cells was tested by incubating increasing amounts of purified ligand Traps with 50 pg/ml IL-6 in XG-1 cultures. The ligand Traps which were tested had been expressed and purified by methods similar to those described above. All of the ligand Traps tested were found to inhibit IL-6-dependent proliferation of XG-1 in a dose dependent manner (FIG. 20). Of the five different Traps tested gp130-Cγ1•IL-6Rα-κ was the most active and essentially display the same neutralizing activity towards IL-6 as the antibody B-E8. As little as a 10-fold molar excess of either gp130-Cγ1•IL-6Rα-κ or B-E8 completely blocked the activity of IL-6 (a reading of A570–650=0.3 AU corresponds to no proliferation of the XG-1 cells). At a 100-fold molar excess all of the ligand Traps tested completely blocked the activity of IL-6. This observed inhibition is highly selective as neither a gp130-Fc-CNTFRα-Fc ligand Trap which blocks CNTF activity, nor gp130-Fc homodimer exhibit any blocking activity towards IL-6 even when used at a 1000-fold molar excess over IL-6 (data not shown). This data demonstrates that the heteromeric immunoglobulin heavy/light chain receptor-based ligand Traps function as selective high affinity antagonists of their cognate ligand.
Example 5
Cloning of Fusion Polypeptide Components
The extracellular domains of the human cytokine receptors were obtained by standard PCR techniques using tissue cDNAs (CLONTECH), cloned into the expression vector, pMT21 (Genetics Institute, Inc.), and the sequences were sequenced by standard techniques using an ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, Calif.). For the IL-4Rα, nucleotides 241 through 868 (corresponding to the amino acids 24–231) from the Genbank sequence, X52425, were cloned. For the IL-2Rγ, nucleotides 15 through 776 (corresponding to amino acids 1–233) from the Genbank sequence, D11086, were cloned. For the IL-6Rα, nucleotides 52 through 1044 (corresponding to the amino acids 1–331) from the Genbank sequence, X52425, were cloned. For gp130, nucleotides 322 through 2112 (corresponding to the amino acids 30–619) from the Genbank sequence, M57230, were cloned. For the IL-1RAcP, nucleotides 1 through 1074 (corresponding to the amino acids 1–358) from the Genbank sequence, AB006357, were cloned. For the IL-1RI, nucleotides 55 through 999 (corresponding to the amino acids 19–333) from the Genbank sequence, X16896, were cloned.
Example 6
Production of Fusion Polypeptides (Cytokine Traps)
The nucleotide sequences encoding the cytokine Traps were constructed from the individual cloned DNAs (described supra) by standard cloning and PCR techniques. In each case, the sequences were constructed in frame such that the sequence encoding the first fusion polypeptide component was fused to the sequence encoding the second fusion polypeptide component followed by an Fc domain (hinge, CH2 and CH3 region of human IgG1) as the multimerizing component. In some cases extra nucleotides were inserted in frame between sequences encoding the first and second fusion polypeptide components to add a linker region between the two components (See FIG. 21A–FIG. 21D, SEQ ID NO: 17-Trap 424; FIG. 24A–FIG. 24F, SEQ ID NO: 23-Trap 412; and FIG. 26A–FIG. 26E, SEQ ID NO: 27-Trap 569).
For the IL-4 Traps, 424 (FIG. 21A–FIG. 21D, SEQ ID NO: 17), 603 (FIG. 22A–FIG. 22D, SEQ ID NO: 19) and 622 (FIG. 23A–FIG. 23D, SEQ ID NO: 21), the IL-2Rγ component is 5′, followed by the IL4Rα component and then the Fc component. For the IL-6 Traps, 412 (FIG. 24A–FIG. 24F, SEQ ID NO: 23) and 616 (FIG. 25A–FIG. 25F, SEQ ID NO: 25), the IL-6Rα component is 5′ followed by the gp130 component and then the Fc domain. For the IL-1 Trap 569 (FIG. 26A–FIG. 26E, SEQ ID NO: 27), the IL-1RAcP component is 5′ followed by the IL-1RI component and then the Fc domain. The final constructs were cloned into the mammalian expression vector pCDNA3.1 (STRATAGENE).
In the 569 sequence (FIG. 26A–FIG. 26E, SEQ ID NO: 27), nucleotides 1–1074 encode the IL1RAcP component, nucleotides 1075–1098 encode a linker region, nucleotides 1099–2043 encode the IL1RI component and nucleotides 2044–2730 encode the Fc domain.
In the 412 sequence (FIG. 24A–FIG. 24F, SEQ ID NO: 23), nucleotides 1–993 encode the IL6Rα component, nucleotides 994–1023 encode a linker region, nucleotides 1024–2814 encode the gp130 component and nucleotides 2815–3504 encode the Fc domain.
In the 616 sequence (FIG. 25A–FIG. 25F, SEQ ID NO: 25), nucleotides 1–993 encode the IL6Rα component, nucleotides 994–2784 encode the gp130 component and nucleotides 2785–3474 encode the Fc domain.
In the 424 (FIG. 21A–FIG. 21D) and 622 (FIG. 23A–FIG. 23D, SEQ ID NO: 17) sequences, nucleotides 1–762 encode the IL2Rγ component, nucleotides 763–771 encode a linker region, nucleotides 772–1395 encode the IL4Rα component and nucleotides 1396–2082 encode the Fc domain.
Finally, in the 603 sequence (FIG. 22A–FIG. 22D, SEQ ID NO: 19), nucleotides 1–762 encode the IL2Rγ component, nucleotides 763–1386 encode the IL4Rα component and nucleotides 1387–2073 encode the Fc domain.
DNA constructs were either transiently transfected into COS cells or stably transfected into CHO cells by standard techniques well known to one of skill in the art. Supernatants were collected and purified by Protein A affinity chromatography and size exclusion chromatography by standard techniques. (See for example Harlow and Lane, Antibodies—A Laboratory Manual, Cold Spring Harbor Laboratory, 1988).
Example 7
IL-4 Bioassay Protocol Using TF-1 (ATCC) Cells
Reagents and Equipment Needed
MTT Dye Solution:
MTT(3-[4,5-Dimethylthiazole-2-yl]) (Sigma catalog# M2128)
Working concentration: Dissolve 5 mg of anhydrous MTT in 200 ml PBS without Ca+2, Mg+2.
Sterile filter and store aliquoted at −20° C.
Solubilization Solution:
For 1000 ml, combine 100 g SDS, 950 ml dH2O, 50 ml Dimethyl Formamide, and 850 μl concentrated HCl.
Filter sterilize with a 0.45 μm filter unit.
Store at room temperature
TF-1 cell Growth Medium:
RPMI 1640, 10% FBS, Pen/Strep, 2 mM L-glutamine
Other:
0.4% Trypan Blue Stain, sterile tubes for dilutions, sterile 96 well cell culture plates (Falcon #3072), hemacytometer, centrifuge, ELISA plate reader, multichannel pipet for 15, 25, 50 and 100 μl volume, sterile reagent reservoirs, sterile pipet tips, gloves.
Assay Protocol
A. Preparation of Assay plates


    1. Prepare sterile 96 well tissue culture plates to contain 50 μl of growth medium per well with various concentrations of IL-4 and 10 nM IL-4 antagonist. This can be done by preparing a working dilution of IL-4 that is 4 times the highest concentration to be assayed. In separate tubes, do a two-fold serial dilution of the IL-4. Add 25 μl of each dilution to one row across the plate (i.e. row A gets highest concentration, row G gets lowest concentration). Add 25 μl of growth medium without IL-4 to row H. Prepare the antagonists to be tested by making a stock that is 4 times the final concentration. Add 25 μl to a triplicate set of IL-4 containing wells (columns 1,2,3, A through H). Be sure to include antagonist in row H.
    2. As a positive control, leave one set with no antagonist. These wells will contain IL-4 and media only.
    3. Incubate the plate for 1–2 hours at 37° C. in a humidified 5% CO2 incubator before preparing cells to be used for assay.

B. Preparation of Cells

    4. Wash cells twice by centrifugation in assay medium free of growth factor.
    5. Determine cell number and trypan blue viability and suspend cells to a final concentration of 8×105/ml in assay medium.
    6. Dispense 50 μl of the cell suspension (40,000 cells) into all wells of the plates. Total volume should now be 100 μl/well.
    7. Incubate the plate at 37° C. for 68 hours in a humidified 5% CO2 incubator.

C. Color Development

    8. After incubating for 68 hours, add 15 μl of the MTT dye solution to each well.
    9. Incubate the plate at 37° C. for 4 hours in a humidified 5% CO2 incubator.
    10. After 4 hours, add 100 μl of the solubilization solution to each well. Allow the plate to stand overnight in a sealed container to completely solubilize the formazan crystals.
    11. Record the absorbance at 570/650 nm.

Results



FIG. 27 shows that an IL-4 Trap designated 4SC375, which is a fusion polypeptide of IL-2Rγ-scb-IL4Rα-FcΔC1, is several orders of magnitude better as an IL-4 antagonist than IL4RαFcΔC1 alone in the TF1 cell bioassay.
FIG. 28 shows that the IL-4 Trap designated 4SC375 shows antagonistic activity in the TF1 cell bioassay equivalent to an IL-4 Trap designated 4SC424 which is a fusion polypeptide of IL-2Rγ-IL4Rα-FcΔC1 having the IL-2Rγ component flush with the IL-4Rα component.
Example 8
IL-6 Bioassay Protocol using XG-1 Cells
Reagents and Equipment Needed
MTT Dye Solution:
MTT(3-[4,5-Dimethylthiazole-2-yl]) (Sigma catalog# M2128)
Working concentration: Dissolve 5 mg of anhydrous MTT in 200 ml PBS without Ca+2, Mg+2.
Sterile filter and store aliquoted at −20° C.
Solubilization Solution:
For 1000 ml, combine 100 g SDS, 950 ml dH2O, 50 ml Dimethyl Formamide, and 850 μl concentrated HCl.
Filter sterilize with at 0.45 μm filter unit.
Store at room temperature
Assay Medium:
RPMI 1640, 10%FBS, Pen/Strep, 2 mM L-glutamine, 50 μM mercapto-ethanol.
Other:
0.4% Trypan Blue Stain, sterile tubes for dilutions, sterile 96 well cell culture plates (Falcon#3072), hemacytometer, centrifuge, ELISA plate reader, multichannel pipet for 15, 25, 50 and 100 μl volume, sterile reagent reservoirs, sterile pipet tips, gloves.
Assay Protocol
A. Preparation of Assay Plates


    1. Prepare sterile 96 well tissue culture plates to contain 50 μl of growth medium per well with various concentrations of IL-6 and 10 nM IL-6 antagonist. This can be done by preparing a working dilution of IL-6 that is 4 times the highest concentration to be assayed. In separate tubes, do a two-fold serial dilution of the IL-6. Add 25 μl of each dilution to one row across the plate (i.e. row A gets highest concentration, row G gets lowest concentration). Add 25 μl of growth medium without IL-6 to row H. Prepare the antagonists to be tested by making a stock that is 4 times the final concentration. Add 25 μl to a triplicate set of IL-6 containing wells (columns 1,2,3, A through H). Be sure to include antagonist in row H. A typical IL-6 titration starts at 200 ng/ml down to 3.1 ng/ml.
    2. As a positive control, leave one set with no antagonist. These wells contain IL-6 and media in place of antagonist.
    3. Incubate the plate 1–2 hours at 37° C. in a humidified 5% CO2 incubator before preparing cells to be used for assay.

B. Preparation of Cells

    4. Wash cells twice by centrifugation (5 min at 1000 RPM) in assay medium free of growth factor.
    5. Determine cell number and trypan blue viability and suspend cells to a final concentration of 8×105/ml in assay medium.
    6. Dispense 50 μl of the cell suspension (40000 cells) into all wells of the plates. Total volume should now be 100 μl/well.
    7. Incubate the plate at 37° C. for 68 hours in a humidified 5% CO2 incubator.

C. Color Development

    8. At 68 hours add 15 μl of the dye solution to each well.
    9. Incubate the plate at 37° C. for 4 hours in a humidified 5% CO2 incubator.
    10. After 4 hours, add 100 μl of the solubilization solution to each well. Allow the plate to stand overnight in a sealed container to completely solubilize the formazan crystals.
    11. Record the absorbance at 570/650 nm.

Results



FIG. 29 shows that the IL6 Trap (6SC412 IL6R-scb-gpx-FcΔC1) described in FIG. 24A–FIG. 24F (SEQ ID NOS: 23 and 24) is a better antagonist of IL-6 in the XG1 bioassay than the neutralizing monoclonal antibody to human IL-6-BE8.
Example 9
MRC5 Bioassay for IL1 Traps
MRC5 human lung fibroblast cells respond to IL-1 by secreting IL-6 and thus were utilized to assay the ability of IL-1 Traps to block the IL-1-dependent production of IL-6. IL1 Trap 1SC569 (FIG. 26A–FIG. 26E, SEQ ID NOS: 27 and 28) was tested against IL-1-RI.Fc which is the extracellular domain of the IL-1 Type I receptor fused to an Fc domain.
MRC5 cells are suspended at 1×105 cells per ml in medium and 0.1 ml of cells are plated (10,000 cells per well) into the wells of a 96 well tissue culture plate. Plates are incubated for 24 hours at 37° C. in a humidified 5% CO2 incubator.
IL-1 Trap and recombinant human IL-1 at varying doses are pre-incubated in a 96 well tissue culture dish and incubated for 2 hours at 37° C. 0.1 ml of this mixture is then added to the 96 well plate containing the MRC5 cells such that the final concentration of IL-1 Trap is 10 nM and the final concentrations of the IL-1 ranges from 2.4 pM to 5 nM. Control wells contain Trap alone or nothing.
Plates are then incubated at 37° C. for 24 hours in a humidified 5% CO2 incubator. Supernatant is collected and assayed for levels of IL-6 using R&D Systems Quantikine Immunoassay Kit according to the manufacturer's instructions.
Results
FIG. 30 shows that the Trap 569 (FIG. 26A–FIG. 26E, SEQ ID NOS: 27 and 28) is able to antagonize the effects of IL-1 and block the IL-6 production from MRC 5 cells upon treatment with IL-1. At a concentration of 10 nM, the Trap 569 is able to block the production of IL-6 up to an IL-1 concentration of 3 nM. In contrast, the IL-1RI.Fc is a much poorer antagonist of IL-1. It is only able to block the effects of IL-1 up to about 10–20 pM. Thus, the Trap 569 is approximately 100× better at blocking IL-1 than IL1RI.Fc.
Example 10
Construction of IL-13/IL-4 Single Chain Traps


    1. To create the IL-13/IL-4 dual Trap designated IL-4Rα.IL-13Rα1.Fc, the human IL-4Rα extracellular domain (corresponding to nucleotides 1–693 of FIGS. 31A–31G, SEQ ID NO: 29) and the human IL-13Rα1 extracellular domain (corresponding to nucleotides 700–1665 of FIGS. 31A–31G, SEQ ID NO: 29) were amplified by standard PCR techniques and ligated into an expression vector pMT21 which contained the human Fc sequence (corresponding to nucleotides 1671–2355 of FIGS. 31A–31G, SEQ ID NO: 29), thus creating a fusion protein consisting of the IL-4Rα, IL-13Rα1, and the hinge, CH2 and CH3 region of human IgG1 from the N to C terminus. In addition, a two amino acid linker (corresponding to nucleotides 694–699 of FIGS. 31A–31G, SEQ ID NO: 29) with the amino acid sequence SerGly was constructed in frame between the IL-4Rα and the IL-13Rα1 and a two amino acid linker (corresponding to nucleotides 1666–1671 of FIGS. 31A–31G, SEQ ID NO: 29) with the amino acid sequence ThrGly was constructed in frame between the IL-13Rα1 and the Fc portion. All sequences were sequence-verified by standard techniques. The IL-4Rα.IL-13Rα1.Fc coding sequence was then subcloned into the expression vector pCDNA3.1 (Stratagene) using standard molecular biology techniques.
    2. To create the IL-13/IL-4 dual Trap designated IL-13Rα1.1L-4Rα.Fc, the IL-13Rα1 extracellular domain (corresponding to nucleotides 1–1029 of FIGS. 32A–32G, SEQ ID NO: 31) and the human IL-4Rα (corresponding to nucleotides 1060–1692 of FIGS. 32A–32G, SEQ ID NO: 31) were amplified by standard PCR techniques and ligated into the expression vector pjFE14, which contains the human Fc sequence (corresponding to nucleotides 1699–2382 of FIGS. 32A–32G, SEQ ID NO: 31) to create a fusion protein consisting of the IL-13Rα1, IL-4Rα, and the hinge, CH2 and CH3 region of human IgG1 from the N to C terminus. In addition, a ten amino acid linker with the amino acid sequence GlyAlaProSerGlyGlyGlyGlyArgPro (SEQ ID NO: 6) (corresponding to nucleotide 1030–1059 of FIGS. 32A–32G, SEQ ID NO: 31) was constructed in frame between the IL-13Rα1 and the IL-4Rα. and a two amino acid linker (corresponding to nucleotides 1693–1698 of FIGS. 32A–32G, SEQ ID NO: 31) with the amino acid sequence SerGly was constructed in frame between IL-4Rα and the Fc portion. All sequences were sequence-verified using standard techniques. The coding sequence of IL-13Rα1.IL-4Rα.Fc was then subcloned into the expression vector pCDNA3.1 (Stratagene) using standard molecular biology techniques.


Example 11
Expression of IL-4Rα.IL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc
Large scale (1L) cultures of the pCAE801 (the DNA vector construct encoding IL-4Rα.IL-13Rα1.Fc) and pCAE802 (the DNA plasmid construct encoding IL-13Rα1. IL-4Rα.Fc) in DH10B cells were grown overnight in LB+ampicillin and the plasmid DNA was extracted using a Qiagen Endofree Mega Kit following the manufacturer's protocol. The concentration of the purified plasmid DNA was determined in a UV spectrophotometer and fluorometer. The plasmid DNA was also verified by digestion of aliquots with BbsI, XmnI and NcoI restriction enzymes. All restriction enzyme digest fragments corresponded to the predicted sizes in a 1% agarose gel.
Forty 15 cm petri plates were seeded with CHO-K1/E1A cells at a density of 4×106cells/plate. Plating media was Gibco Ham's F-12 w/10% Hyclone Fetal Bovine Serum (FBS)+penicillin/streptomycin and supplemented with glutamine. The following day each plate was transfected with 6 μg of pCAE801, or pCAE802, using Gibco Optimem and Gibco Lipofectamine in 12 ml volume, following the manufacturer's protocol. Four hours after adding the transfection mix to the cells 12 ml/plate of Optimem w/10% FBS was added. Plates were incubated at 37° C. in a 5% CO2 incubator overnight. The following day the media was removed from each plate and 25 ml expression media (Gibco CHO-S-SFM II w/glutamine +1 mM sodium butyrate) was added. The plates were incubated at 37° C. for 3 days.
After 3 days of incubation the media was removed from each plate and centrifuged at 400 rpm in a swinging bucket rotor to pellet cells. The supernatant was decanted into sterile 1L bottles and expressed protein was purified as described infra.
Example 12
Purification of IL-4Rα.IL-13Rα1.Fc AND IL-13Rα1.IL-4Rα.Fc Protein from Culture Media
1. Purification of IL-4Rα.IL-13Rα1.Fc.
Human IL-4Rα.IL-13Rα1.Fc was transiently expressed in CHO cells and supernatants were harvested from plate transfections as described supra. Expression of the secreted protein was determined by a sandwich ELISA using goat anti-hIgG (γ chain specific; Sigma 1–3382) and goat anti-hIgG (Fc specific)-FITC conjugate (Sigma F9512) capture and report antibodies, respectively. The yield ranged from 5.8 to 9.2 mg (average of 7.5 mg) per liter of conditioned media. CompleteTM protease inhibitor tablets (Roche Diagnostics Corp.) were dissolved into the media (1 tablet/L). The conditioned media was sterile filtered (0.22 μm pore size) prior to loading onto a pre-equilibrated, 5 mL HiTrap® Protein A affinity column (Amersham Pharmacia Biotech) in Dulbecco's PBS buffer (Life Technologies), pH 7.4 at 4° C. The flow rate was  ̃1–2 mL/min. The column was extensively washed with PBS buffer to remove nonspecifically bound proteins from the column. IL-4Rα.IL-13Rα1.Fc_was eluted using 20 mM sodium citrate, 150 mM NaCl, pH 3.5. The eluate was immediately neutralized by titrating with 1 M Tris-OH. The fractions containing protein were pooled and immediately dialyzed in PBS buffer, pH 7.4 at 4° C. The recovery from Protein A purification was 6.8 mg (73%). IL-4Rα.IL-13Rα1.Fc was further purified by size exclusion chromatography using a superose 6 column (25 mL bed volume; Amersham Pharmacia Biotech) pre-equilibrated in PBS, 5% v/v glycerol, pH 7.4 at ambient temperature. The flow rate was 0.5 mL/min. Protein fractions were assessed from a Coomassie stained non-reduced and reduced SDS-PAGE (Novex NuPAGE 4–12% Bis-Tris gels). Fractions were conservatively pooled to reduce the amount of aggregated protein. The overall yield was 51% (4.4 mg) with a purity of 97% as judged by SDS-PAGE. Purified IL-4Rα.IL-13Rα1.Fc was analyzed by non-reduced and reduced SDS-PAGE (4–12% Bis-Tris), analytical size exclusion chromatography (Tosohaas TSKG4000SWXL), N-terminal sequencing, and immunoblotting with goat anti-hIgG-HRP conjugate (Promega W403B), and also mouse monoclonal anti-hIL-4R (R&D MAB230) followed by anti-mlgG-HRP conjugate (Promega W402B) as the secondary antibody.
2. Purification of IL-13Rα1. IL-4Rα.Fc
Human IL-13Rα1.IL-4Rα.Fc was transiently expressed in CHO cells and supernatants were harvested from plate transfections as described supra. Expression of the secreted protein was determined by a sandwich ELISA using goat anti-hIgG (γ chain specific; Sigma 1–3382) and goat anti-hIgG (Fc specific)-FITC conjugate (Sigma F9512) capture and report antibodies, respectively. The yield was 8.8 mg per liter of conditioned media. CompleteTM protease inhibitor tablets (Roche Diagnostics Corp.) were dissolved into the media (1 tablet/L). The conditioned media was sterile filtered (0.22 μm pore size) prior to loading onto a pre-equilibrated, 5 mL HiTrap® Protein A affinity column (Amersham Pharmacia Biotech) in Dulbecco's PBS buffer (Life Technologies), pH 7.4 at 4° C. The flow rate was  ̃1–2 mL/min. The column was extensively washed with PBS buffer to remove nonspecifically bound proteins from the column. IL-13Rα1. IL-4Rα.Fc was eluted using 20 mM sodium citrate, 150 mM NaCl, pH 3.5. The eluate was immediately neutralized by titrating with 1 M Tris-OH. The fractions containing protein were pooled and immediately dialyzed in PBS buffer, pH 7.4 at 4° C. The recovery from Protein A purification was 3.8 mg (43%). IL-13Rα1. IL-4Rα.Fc was further purified by size exclusion chromatography using a superose 6 column (25 mL bed volume; Amersham Pharmacia Biotech) pre-equilibrated in PBS, 5% v/v glycerol, pH 7.4 at ambient temperature. The flow rate was 0.5 mL/min. Protein fractions were assessed from a Coomassie stained non-reduced and reduced SDS-PAGE (Novex NuPAGE 4–12% Bis-Tris gels). Fractions were conservatively pooled to reduce the amount of aggregated protein. The overall yield was 17% (1.5 mg) with a purity of 95% as judged by SDS-PAGE. Purified IL-13Rα1. IL-4Rα.Fc was analyzed by non-reduced and reduced SDS-PAGE (4–12% Bis-Tris), analytical size exclusion chromatography (Tosohaas TSKG4000SWXL), N-terminal sequencing, and immunoblotting with goat anti-hIgG-HRP conjugate (Promega W403B), and also mouse monoclonal anti-hIL-4Rα (R&D MAB230) followed by anti-mIgG-HRP conjugate (Promega W402B) as the secondary antibody.
Example 13
Blocking of IL-4 and IL-13 by IL-4Rα.IL-13Rα1.Fc and IL-13Rα1. IL-4Rα.Fc
Materials and Methods
TF1 Bioassay. TF1 cells were maintained in growth media (10 ng/ml GM-CSF, RPMI 1640, 10% FBS, L-glutamine, Penicillin, Streptomycin). For the bioassay, cells were washed 2 times in assay media (as above but without GM-CSF) and then plated at 2×105 cells in 50 μl of assay media. The purified IL-4Rα.IL-13Rα1.Fc and IL-13Rα1. IL-4Rα.Fc proteins were diluted into assay media at a concentration of 40 nM. 25 ul of each of the Traps was added to the cells. Either IL-13 or IL-4 were diluted to 40 nM in assay media and then 2-fold dilution series in assay media were made. 25 μl of either IL-13 or IL-4 was then added to the wells containing the cells and the Traps. Cells were then incubated at 37° C., 5% CO2 for  ̃70 hrs. The extent of TF1 cell proliferation was measured by the MTS assay according to the manufacturer's protocol (Promega, Inc.).
Results
The ability of the IL-4Rα.IL-13Rα1.Fc and IL-13Rα.IL-4Rα.Fc Traps to block both human IL-13 and human IL-4 activity was measured in the TF1 bioassay described supra. IL-13 stimulates proliferation of TF1 cells, with half-maximal growth at a concentration of 0.2 nM. Addition of either IL-4Rα.IL-13Rα1.Fc or IL-13Rα1. IL-4Rα.Fc Trap at a concentration of 10 nM blocks IL-13-induced growth up to  ̃2 nM (FIG. 33). At an IL-13 concentration of  ̃4–5 nM the growth of TF1 cells is inhibited by 50%. TF1 cells are more sensitive to IL-4, which stimulates their proliferation with half-maximal growth at  ̃0.02 nM. Addition of either IL-4Rα.IL-13Rα1.Fc or IL-13Rα1. IL-4Rα.Fc at a concentration of 10 nM blocks IL-4-induced growth up to  ̃1 nM (FIG. 34). At an IL-4 concentration of  ̃3–4 nM the growth of TF1 cells is inhibited by 50%. These results show that both IL-4Rα.IL-13Rα1.Fc and IL-13Rα1.IL-4Rα.Fc can block the ability of both IL-13 and IL-4 to stimulate cellular responses.
Example 14
Blocking of Injected IL-1 by IL-1 Trap In Vivo
IL-1 is a pro-inflammatory cytokine. Systemic administration of IL-1 has been shown to elicit acute responses in animals, including transient hyperglycemia, hypoinsulinemia, fever, anorexia, and increased serum levels of interleukin-6 (IL-6) (Reimers, 1998). Since mice are responsive to both murine and human IL-1, human IL-1 can be used and in vivo binding effects of human specific IL-1 antagonists can be evaluated. This acute mouse model was used to determine the ability of a human IL-1 Trap to antagonize the in vivo effects of exogenously administered human IL-1. This provides a rapid indication of in vivo efficacy of the human IL-1 Trap and can be used as an assay to help molecule selection.
Experimental Design:
Mice were given subcutaneous injections of human IL-1 (0.3 μg/kg). Twenty-four hours prior to human IL-1 injection, the animals were pre-treated with either vehicle or 150-fold molar excess of human IL-1 Trap (0.54 mg/kg). Two hours prior to sacrifice (26 hrs), the mice were given a second injection of human IL-1 (0.3 μg/kg). Blood samples were collected at various time points and sera were assayed for IL-6 levels.
Results
Exogenous administration of human IL-1 resulted a dramatic induction of serum IL-6 levels. At 150-fold molar excess, the human IL-1 Trap completely blocked the IL-6 increase (FIG. 35). Furthermore, the effects of the human IL-1 Trap persisted for at least another 24 hours, preventing an IL-6 increase even when IL-1 was re-administered (FIG. 35). Such long-lasting efficacy suggests that daily injection of an IL-1 Trap may not be necessary for chronic applications.
Example 15
Evaluating the Ability of an IL-4 Trap to Block the Physiological Responses to Human IL-4 In Cynomologus Monkeys.
Systemic administration of human IL-4 elicits systemic responses in Cynomologus monkeys (Gundel et al., 1996). Thus, the effectiveness of the IL-4 Trap in blocking human IL-4 can be demonstrated by measuring these responses.
Experimental Design:
The experiment consisted of 3 parts: human IL-4+vehicle (part 1), human IL-4+IL-4 Trap (part 2), and human IL-4+ vehicle (part 3). Human IL-4 (25 μg/kg) was injected subcutaneously twice daily for 4 days and IL-4 Trap (8 mg/kg) and vehicle were given intravenously daily for 5 days, beginning 1 day prior to human IL-4 administration. Whole blood was collected daily for flow cytometry analysis for CD16 and plasma was obtained to assay for the cytokine monocyte chemotactic protein 1 (MCP-1). CD16 and MCP-1 are markers of IL-4-mediated inflammation in both humans and monkeys.
Results
In the presence of human IL-4, MCP-1 increased 2.5-fold and was significantly blocked by the IL-4 Trap (FIG. 36A). Similarly, the decrease in the percent of CD16 positive lymphocytes in peripheral blood was attenuated by the IL-4 Trap (FIG. 36B). After a rest period, the monkeys were re-injected with human IL-4 and the responsiveness of the animals to human IL-4 was re-confirmed (FIGS. 36A and 36B), suggesting that inhibition of the MCP-1 and CD 16 responses is specifically mediated by the IL-4 Trap.
Example 16
The Effects of IL-4 Trap on IL-4-Induced IgE
Secretion
It has been shown that injection of anti-mouse IgD antibody stimulates an IL-4-mediated IgE increase in normal mice. This model has been widely used to evaluate IL-4 antagonists, such as soluble IL-4 receptor and anti-IL-4 monoclonal antibodies (Sato et al., 1993). We decided to use this model to evaluate the ability if the IL-4 Trap to block IL-4-mediated increases of IgE.
Experimental Design:
BALB/C mice injected with anti-mouse IgD (100 μl/mouse, s.c.) were randomly divided into 3 groups. Each received (on days 3–5) either vehicle, murine IL-4 Trap (1 mg/kg, s.c.), or a monoclonal antibody to mouse IL-4 (1 mg/kg, s.c.). Serum was collected at various time points and assayed for IgE levels.
Results
Treatment with the murine IL-4 Trap or the mouse IL-4 antibody both significantly antagonized the IL-4-mediated IgE increase in this mouse model (FIG. 37). This suggests that the murine IL-4 Trap binds murine IL-4 and antagonizes physiological responses elicited by endogenous IL-4 in vivo.
Example 17
Construction of Additional IL-4/IL-13 Traps
The following IL-4/IL-13 Traps were constructed using standard molecular biology techniques familiar to the skilled artisan.
IL-4/IL-13 Trap 933
The IL-4/IL-13 Trap 933 sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides −78 to 951 of FIGS. 38A–38H, SEQ ID NO: 33), followed by the extracellular domain of human IL-4Rα (nucleotides 952–1575 of FIGS. 38A–38H, SEQ ID NO: 33) containing a mutation at nucleotide 1501 (T->A) to change a cysteine to a serine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides 1576–2265 of FIGS. 38A–38H, SEQ ID NO: 33) containing a mutation at nucleotides 1579–1581 (TGT->GGA) to change a cysteine to a glycine. FIGS. 38A–38H sets forth the deduced amino acid sequence (SEQ ID NO: 34) of IL-4/IL-13 Trap 933.
IL-4/IL-13 Trap 943
The IL-4/IL-13 Trap 943 sequence consists of the extracellular domain of human IL-4Rα (nucleotides −69 to 624 of FIGS. 39A–39G, SEQ ID NO: 39) containing a mutation at nucleotide 550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides 625–1575 of FIGS. 39A–39G, SEQ ID NO: 39) followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides 1576–2262 of FIGS. 39A–39G, SEQ ID NO: 39) containing a mutation at nucleotides 1576–1578 (TGT->GGT) to change a cysteine to a glycine. FIGS. 39A–39G sets forth the deduced amino acid sequence (SEQ ID NO: 40) of IL-4/IL-13 Trap 943.
IL-4/IL-13 Trap 1126
The IL-4/IL-13 Trap 1126 sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides −78 to 951 of FIGS. 40A–40I, SEQ ID NO: 37), containing a mutation at nucleotide58 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-4Rα (nucleotides 952–1575 of FIGS. 40A–40I, SEQ ID NO: 37) containing a mutation at nucleotide 1501 (T->A) to change a cysteine to a serine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides 1576–2265 of FIGS. 40A–40I, SEQ ID NO: 37) containing a mutation at nucleotides 1579–1581 (TGT->GGA) to change a cysteine to a glycine. FIGS. 40A–40I sets forth the deduced amino acid sequence (SEQ ID NO: 38) of IL-4/IL-13 Trap 1126.
IL-4/IL-13 Trap 1128
The IL-4/IL-13 Trap 1128 sequence consists of the extracellular domain of human IL-4Rα (nucleotides −69 to 624 of FIGS. 41A–41P, SEQ ID NO: 35) containing a mutation at nucleotide 550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides 625–1575 of FIGS. 41A–41P, SEQ ID NO: 35) containing a mutation at nucleotide 682 (T->A) to change a cysteine to a serine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides 1576–2262 of FIGS. 41A–41P, SEQ ID NO: 35) containing a mutation at nucleotides 1576–1578 (TGT->GGT) to change a cysteine to a glycine. FIGS. 41A–41P sets forth the deduced amino acid sequence (SEQ ID NO: 36) of IL-4/IL-13 Trap 1128.
IL-4/IL-13 Trap 1130
The IL-4/IL-13 Trap 1130 sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides −78 to 951 of FIGS. 42A–42I, SEQ ID NO: 41), containing a mutation at nucleotides 58–60 (TGC->GCG) to change a cysteine to an alanine, followed by the extracellular domain of human IL-4Rα (nucleotides 952–1575 of FIGS. 42A–42I, SEQ ID NO: 41), containing a mutation at nucleotide 1501 (T->A) to change a cysteine to a serine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides 1576–2265 of FIGS. 42A–42I, SEQ ID NO: 41) containing a mutation at nucleotides 1579–1581 (TGT->GGA) to change a cysteine to a glycine. FIGS. 42A–42I sets forth the deduced amino acid sequence (SEQ ID NO: 42) of IL-4/IL-13 Trap 1130.
IL-4/IL-13 Trap 1132
The IL-4/IL-13 Trap 1132 sequence consists of the extracellular domain of human IL-4Rα (nucleotides −69 to 624 of FIGS. 43A–43P, SEQ ID NO: 43) containing a mutation at nucleotide 550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides 625–1575 of FIGS. 43A–43P, SEQ ID NO: 43) containing a mutation at nucleotides 682–684 (TGC->GCG) to change a cysteine to an alanine, followed by part of the hinge region, the CH2 and CH3 domains of human IgG1 (nucleotides 1576–2262 of FIGS. 43A–43P, SEQ ID NO: 43) containing a mutation at nucleotides 1576–1578 (TGT->GGT) to change a cysteine to a glycine. FIGS. 43A–43P sets forth the deduced amino acid sequence (SEQ ID NO: 44) of IL-4/IL-13 Trap 1132.
IL-4/IL-13 Trap 1199
The IL-4/IL-13 Trap 1199 sequence consists of the extracellular domain of human IL-4Rα (nucleotides −69 to 624 of FIGS. 44A–44I, SEQ ID NO: 45) containing a mutation at nucleotide 550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides 625–1575 of FIGS. 44A–44I, SEQ ID NO: 45) containing a mutation at nucleotide 682–684 (TGC->GCG) to change a cysteine to an alanine, followed by a stretch of amino acids (nucleotides 1576–1578 of FIGS. 44A–44I, SEQ ID NO: 45), followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides 1579–2268 of FIGS. 44A–44I, SEQ ID NO: 45). FIGS. 44A–44I sets forth the deduced amino acid sequence (SEQ ID NO: 46) of IL-4/IL-13 Trap 1199.
IL-4/IL-13 Trap 1244
The IL-4/IL-13 Trap 1244 sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides −78 to 951 of FIGS. 45A–45I, SEQ ID NO: 47), containing a mutation at nucleotide 58–60 (TGC->GCG) to change a cysteine to an alanine, followed by the extracellular domain of human IL-4Rα (nucleotides 952–1575 of FIGS. 45A–45I, SEQ ID NO: 47) containing a mutation at nucleotide 1501 (T->A) to change a cysteine to a serine, followed by a stretch of amino acids (nucleotides 1576–1581 of FIGS. 45A–45I, SEQ ID NO: 47), followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides 1582–2271 of FIGS. 45A–45I, SEQ ID NO: 47). FIGS. 45A–45I sets forth the deduced amino acid sequence Trap 1244.
IL-4/IL-13 Trap 1245
The IL-4/IL-13 Trap 1245 sequence consists of the extracellular domain of human IL-4Rα (nucleotides −69 to 624 of FIGS. 46A–46I, SEQ ID NO: 49) containing a mutation at nucleotide 550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides 625–1575 of FIGS. 46A–46I, SEQ ID NO: 49) containing a mutation at nucleotide 682 (T->A) to change a cysteine to an serine, followed by a stretch of amino acids (nucleotides 1576–1578 of FIGS. 46A–46I, SEQ ID NO: 49), followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides 1579–2268 of FIGS. 46A–46I, SEQ ID NO: 49). FIGS. 46A–46I sets forth the deduced amino acid sequence (SEQ ID NO: 50) of IL-4/IL-13 Trap 1245.
IL-4/IL-13 Trap 1246
The IL-4/IL-13 Trap 1246 sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides −78 to 951 of FIGS. 47A–47I, SEQ ID NO: 51) containing a mutation at nucleotide 58 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-4Rα (nucleotides 952–1575 of FIGS. 47A–47I, SEQ ID NO: 51) containing a mutation at nucleotide 1501 (T->A) to change a cysteine to a serine, followed by a stretch of amino acids (nucleotides 1576–1581 of FIGS. 47A–47I, SEQ ID NO: 51), followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides 1582-2271 of FIGS. 47A–47I, SEQ ID NO: 51). FIGS. 47A–47I sets forth the deduced amino acid sequence (SEQ ID NO: 52) of IL-4/IL-13 Trap 1246.
IL-4/IL-13 Trap 1244-B
The IL-4/IL-13 Trap 1244-B sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides −78 to 951 of FIGS. 52A–52H, SEQ ID NO: 53), containing a mutation at nucleotide 58–60 (TGC->GCG) to change a cysteine to an alanine, followed by the extracellular domain of human IL-4Rα (nucleotides 952–1575 of FIGS. 52A–52H, SEQ ID NO: 53) containing a mutation at nucleotide 1501 (T->A) to change a cysteine to a serine, followed by a stretch of amino acids (nucleotides 1576–1581 of FIGS. 52A–52H, SEQ ID NO: 53), followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides 1582–2271 of FIGS. 52A–52H, SEQ ID NO: 53) containing a mutation at nucleotide 1609 (T->C) to change a serine to a proline. FIGS. 52A–52H sets forth the deduced amino acid sequence (SEQ ID NO: 54) of IL-4/IL-13 Trap 1244-B.
IL-4/IL-13 Trap 1245-B
The IL-4/IL-13 Trap 1245-B sequence consists of the extracellular domain of human IL-4Rα (nucleotides −69 to 624 of FIGS. 53A–53I, SEQ ID NO: 55) containing a mutation at nucleotide 550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides 625–1575 of FIGS. 53A–53I, SEQ ID NO: 55) containing a mutation at nucleotide 682 (T->A) to change a cysteine to an serine, followed by a stretch of amino acids (nucleotides 1576–1578 of FIGS. 53A–53I, SEQ ID NO: 55), followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides 1579–2268 of FIGS. 53A–53I, SEQ ID NO: 55) containing a mutation at nucleotide 1606 (T->C) to change a serine to a proline. FIGS. 53A–53I sets forth the deduced amino acid sequence (SEQ ID NO: 56) of IL-4/IL-13 Trap 1245-B.
IL-4/IL-13 Trap 1246-B
The IL-4/IL-13 Trap 1246-B sequence consists of the extracellular domain of human IL-13Rα1 (nucleotides −78 to 951 of FIGS. 54A–54H, SEQ ID NO: 57) containing a mutation at nucleotide 58 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-4Rα (nucleotides 952–1575 of FIGS. 54A–54H, SEQ ID NO: 57) containing a mutation at nucleotide 1501 (T->A) to change a cysteine to a serine, followed by a stretch of amino acids (nucleotides 1576–1581 of FIGS. 54A–54H, SEQ ID NO: 57), followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides 1582–2271 of FIGS. 54A–54H, SEQ ID NO: 57) containing a mutation at nucleotide 1609 (T->C) to change a serine to a proline. FIGS. 54A–54H sets forth the deduced amino acid sequence (SEQ ID NO: 58) of IL-4/IL-13 Trap 1246-B.
IL-4/IL-13 Trap 1268
The IL-4/IL-13 Trap 1268 sequence consists of the extracellular domain of human IL-4Rα (nucleotides −69 to 624 of FIGS. 55A–55H, SEQ ID NO: 59) containing a mutation at nucleotide 550 (T->A) to change a cysteine to a serine, followed by the extracellular domain of human IL-13Rα1 (nucleotides 625–1575 of FIGS. 55A–55H, SEQ ID NO: 59) containing a mutation at nucleotide 682–684 (TGC->GCG) to change a cysteine to an alanine, followed by a stretch of amino acids (nucleotides 1576–1578 of FIGS. 55A–55H, SEQ ID NO: 59),followed by the hinge region, the CH2 and CH3 domains of human IgG4 (nucleotides 1579–2268 of FIGS. 55A–55H, SEQ ID NO: 59) containing a mutation at nucleotide 1606 (T->C) to change a serine to a proline. FIGS. 55A–55H sets forth the deduced amino acid sequence (SEQ ID NO: 60) of IL-4/IL-13 Trap 1268.
In addition to the sequences described supra and in the associated figures, the following modifications to those sequences are also contemplated by the subject invention:
SG Insertion:
For IL-4/IL-13 Traps 943, 1132, 1199, 1268, 1128, 1245, and 1245-B an insertion of the nucleotides TCC GGA between nucleotides 624 and 625 would add a Ser Gly stretch of amino acids between the two receptor domains of the Trap.
For IL-4/IL-13 Traps 933, 1130, 1244, 1244-B, 1126, 1246, and 1246-B, an insertion of the nucleotides TCC GGA between nucleotides 951 and 952 would add a Ser Gly stretch of amino acids between the two receptor domains of the Trap.
IL13Rα1 Alternative:
For IL-4/IL-13 Traps 943, 1132, 1199, 1268, 1128, 1245, and 1245-B a change at nucleotide 935 from C to T would change the amino acid from Thr to IIe.
For IL-4/IL-13 Traps 933, 1130, 1244, 1244-B, 1126, 1246, and 1246-B, a change at nucleotide 311 from C to T would change the amino acid from Thr to II e.
IL4Rα Alternative:
For IL-4/IL-13 Traps 943, 1132, 1199, 1268, 1128, 1245, and 1245-B, a change at nucleotide 154 from A to G would change the amino acid from IIe to Val.
For IL-4/IL-13 Traps 933, 1130, 1244, 1244-B, 1126, 1246, and 1246-B, a change at nucleotide 1105 from A to G would change the amino acid from IIe to Val.
The skilled artisan will recognize that any combination of the above-described modifications within a Trap are also contemplated by the present invention even if each and every combination is not explicitly set forth herein.
Example 18
IL-4/IL-13 Trap Properties
The IL-4/IL-13 Trap 943 blocked IL-4 and IL-13 in a TF1 bioassay more potently than the IL-4/IL-13 Trap 933. In addition, in CHO transient transfection systems, IL-4/IL-13 Trap 943 had a slightly higher protein expression level.
Disulfide mapping and stoichiometry using standard BIAcore methodologies suggested that the IL-4/IL-13 Trap 933 and IL-4/IL-13 Trap 943 molecules were misfolded. Therefore, second generation of IL-4/IL-13 Traps were constructed. It was found that the IL-4/IL-13 Trap constructs 1126, 1128, 1130, and 1132, in which the cysteine at position 20 of mature human IL-13Rα1 was mutated to either an alanine or a serine, exhibited less aggregation upon expression, had  ̃2 to 3-fold better activity than IL-4/IL-13 Trap 943 in the TF1 bioassay in blocking both IL-4 and IL-13, and exhibited a consistent and homogenous pattern of disulfide formation.
The IL-4/IL-13 Trap 1132 molecule had additional advantages over IL-4/IL-13 Traps 1126, 1128, and 1130. A higher percentage of the total protein (>95%) had the correct N-terminal sequence as compared to the IL-4/IL-13 Traps 1126 or 1130 (80–90%). Stoichiometric studies indicated a stoichiometry of 1 for the IL-4/IL-13 Trap 1132 whereas the IL-4/IL-13 Trap 1130 showed a stoichiometry of 1.5. Preliminary mouse pharmacokinetic experiments suggest that the IL-4/IL-13 Trap 1132 molecule has a higher Cmax (maximal serum concentration) and a longer t1/2  (serum half-life) than the others. The IgG4 versions of the IL-4/IL-13 Traps containing the cysteine mutations may be preferred if it is desired to reduce the effector functions of the Fc portion of the Traps. The cysteine to serine mutation in IL-4/IL-13 Traps 1126 and 1128 molecules creates a novel N-glycosylation site which may be desirable in certain circumstances.
Example 19
IL-4/IL-13 Traps Potently Block both IL-4 and IL-13 in TF1 Bioassays.
Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (E. coli; Preprotech) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for  ̃3 days at 37° C., 5% CO2. MTS was added to each well as described supra, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. FIG. 48 shows the results of this experiment. The IL-4/IL-13 Trap 1132 can block IL-13 more potently than the IL-4/IL-13 Trap 943. IL-4/IL-13 Trap 1132 exhibits an IC50 of 64 pM as compared to 184 pM for Trap 943.
The above experiment was performed with E. coli-produced IL-13. To confirm that the IL-4/IL-13 Trap will bind human IL-13 in vivo, IL-13 was produced and purified from a mammalian cell line (CHO). The CHO-derived human IL-13 was then utilized in the TF1 bioassay to determine the ability of the IL-4/IL-13 Trap to bind and block activity. The IL-4/IL-13 Trap 1132 displays a higher affinity for human IL-13 produced by CHO cells (IC50=17 pM) than for human IL-13 made in E. coli (64 pM). This result predicts that the IL-4/IL-13 Trap will successfully bind human IL-13 with high affinity in vivo.
Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 40 pM recombinant human IL-4 (E. coli; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for  ̃3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. FIG. 49 shows the results of this experiment. The IL-4/IL-13 Trap 1132 can block IL-4 more potently than the IL-4/IL-13 Trap 943. IL-4/IL-13 Trap 1132 exhibits an IC50 of 95 pM as compared to 222 pM for Trap 943.
As shown in FIG. 50, IL-4/IL-13 Trap 1132 displays a higher affinity for Applicants' rhIL13. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 Applicants' own material (CHO) or Pharmingen (E. coli) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for  ̃3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. IL-4/IL-13 Trap 1132 has an IC50 of 16 pM which indicates a Kd of  ̃9 pM.
As shown in FIG. 51, IL-4/IL-13 Trap 1132 can block hIL13 more potently than IL-4/IL-13 Trap 943 with Applicants' own rhIL13. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (CHO; Applicants' own material) and varying concentrations of IL-4/IL-13 Trap 943 or 1132 for  ̃3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. IL-4/IL-13 Trap 1132 has an IC50 of 17 pM as compared to 33 pM for 943.
As shown in FIG. 56, IL-4/IL-13 Trap 1132, IL-4/IL-13 Trap 1199 and IL-4/IL-13 Trap 1268 are equally potent in blocking IL13. Triplicate plates of TF1 cells (20,000 cells/well) were incubated with 15 pM recombinant human IL-13 (E. coli; Pharmingen) and varying concentrations of IL-4/IL-13 Trap 1132, 1199 or 1268 for  ̃3 days at 37° C., 5% CO2. MTS was added to each well, incubated at 37° C., 5% CO2 for 4 hrs. and cell proliferation was measured as OD at 490 nm. Relative cell proliferation as a percentage of the proliferation of cells in the absence of IL-4/IL-13 Trap is plotted on the y-axis. The IL-4/IL-13 Traps 1132, 1199 and 1268 all block IL-13 with the same potency, indicating that the isotype of the Fc portion does not affect the ability of IL-4/IL-13 Trap to block IL-13 in vitro.
The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

## Claims

1. A fusion polypeptide having the amino acid sequence of SEQ ID NO: 30, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13 to form a nonfunctional complex.

2. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 1.

3. The isolated nucleic acid of claim 2, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:29.

4. A fusion polypeptide having the amino acid sequence of SEQ ID NO: 32, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13to form a nonfunctional complex.

5. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 4.

6. The isolated nucleic acid of claim 5, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:31.

7. A fusion polypeptide having the amino acid sequence of SEQ ID NO:34, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13to form a nonfunctional complex.

8. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 7.

9. The isolated nucleic acid of claim 8, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:33.

10. The isolated nucleic acid of claim 9, wherein nucleotide 311 is changed from C to T.

11. The isolated nucleic acid of claim 9, wherein nucleotide 1105 is changed from A to G.

12. The isolated nucleic acid of claim 9, wherein nucleotides TCCGGA are inserted between nucleotides 951 and 952.

13. The isolated nucleic acid of claim 9, wherein nucleotides TCCGGA are inserted between nucleotides 951 and 952, nucleotide 311 is changed from C to T, and nucleotide 1105 is changed from A to G.

14. A fusion polypeptide having the amino acid sequence of SEQ ID NO:36, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13to form a nonfunctional complex.

15. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 14.

16. The isolated nucleic acid of claim 15, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:35.

17. The isolated nucleic acid of claim 16, wherein nucleotide 935 is changed from C to T.

18. The isolated nucleic acid of claim 16, wherein nucleotides TCCGGA are inserted between nucleotides 624 and 625.

19. The isolated nucleic acid of claim 16, wherein nucleotide 154 is changed from A to G.

20. The isolated nucleic acid of claim 16, wherein nucleotide 935 is changed from C to T, nucleotides TCCGGA are inserted between nucleotides 624 and 625, and nucleotide 154 is changed from A to G.

21. A fusion polypeptide having the amino acid sequence of SEQ ID NO:38, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and IL-13to form a nonfunctional complex.

22. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 21.

23. The isolated nucleic acid of claim 22, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:37.

24. The isolated nucleic acid of claim 23, wherein nucleotide 311 is changed from C to T.

25. The isolated nucleic acid of claim 23, wherein nucleotide 1105 is changed from A to G.

26. The isolated nucleic acid of claim 23, wherein nucleotides TCCGGA are inserted between nucleotides 951 and 952.

27. The isolated nucleic acid of claim 23, wherein nucleotides TCCGGA are inserted between nucleotides 951 and 952, nucleotide 311 is changed from C to T, and nucleotide 1105 is changed from A to G.

28. A fusion polypeptide having the amino acid sequence of SEQ ID NO:40, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13to form a nonfunctional complex.

29. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 28.

30. The isolated nucleic acid of claim 29, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:39.

31. The isolated nucleic acid of claim 30, wherein nucleotide 935 is changed from C to T.

32. The isolated nucleic acid of claim 30, wherein nucleotides TCCGGA are inserted between nucleotides 624 and 625.

33. The isolated nucleic acid of claim 30, wherein nucleotide 154 is changed from A to G.

34. The isolated nucleic acid of claim 30, wherein nucleotide 935 is changed from C to T, nucleotides TCCGGA are inserted between nucleotides 624 and 625, and nucleotide 154 is changed from A to G.

35. A fusion polypeptide having the amino acid sequence of SEQ ID NO:42, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13 to form a nonfunctional complex.

36. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 35.

37. The isolated nucleic acid of claim 36, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:41.

38. The isolated nucleic acid of claim 37, wherein nucleotide 311 is changed from C to T.

39. The isolated nucleic acid of claim 37, wherein nucleotide 1105 is changed from A to G.

40. The isolated nucleic acid of claim 37, wherein nucleotides TCCGGA are inserted between nucleotides 951 and 952.

41. The isolated nucleic acid of claim 37, wherein nucleotides TCCGGA are inserted between nucleotides 951 and 952, nucleotide 311 is changed from C to T, and nucleotide 1105 is changed from A to G.

42. A fusion polypeptide having the amino acid sequence of SEQ ID NO:44, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13 to form a nonfunctional complex.

43. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 42.

44. The isolated nucleic acid of claim 43, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:43.

45. The isolated nucleic acid of claim 44, wherein nucleotide 935 is changed from C to T.

46. The isolated nucleic acid of claim 44, wherein nucleotides TCCGGA are inserted between nucleotides 624 and 625.

47. The isolated nucleic acid of claim 44, wherein nucleotide 154 is changed from A to G.

48. The isolated nucleic acid of claim 44, wherein nucleotide 935 is changed from C to T, nucleotides TCCGGA are inserted between nucleotides 624 and 625, and nucleotide 154 is changed from A to G.

49. A fusion polypeptide having the amino acid sequence of SEQ ID NO:46, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13 to form a nonfunctional complex.

50. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 49.

51. The isolated nucleic acid of claim 50, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:45.

52. A fusion polypeptide having the amino acid sequence of SEQ ID NO:48, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13 to form a nonfunctional complex.

53. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 52.

54. The isolated nucleic acid of claim 53, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:47.

55. A fusion polypeptide having the amino acid sequence of SEQ ID NO:50, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13 to form a nonfunctional complex.

56. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 55.

57. The isolated nucleic acid of claim 56, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:49.

58. A fusion polypeptide having the amino acid sequence of SEQ ID NO:52, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13 to form a nonfunctional complex.

59. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 58.

60. The isolated nucleic acid of claim 59, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:51.

61. A fusion polypeptide having the amino acid sequence of SEQ ID NO:54, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13 to form a nonfunctional complex.

62. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 61.

63. The isolated nucleic acid of claim 62, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:53.

64. A fusion polypeptide having the amino acid sequence of SEQ ID NO:56, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13 to form a nonfunctional complex.

65. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 64.

66. The isolated nucleic acid of claim 65, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:55.

67. A fusion polypeptide having the amino acid sequence of SEQ ID NO:58, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13 to form a nonfunctional complex.

68. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 67.

69. The isolated nucleic acid of claim 68, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:57.

70. A fusion polypeptide having the amino acid sequence of SEQ ID NO:60, wherein the fusion polypeptide forms a multimer capable of binding interleukin-4 (IL-4) and/or IL-13 to form a nonfunctional complex.

71. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 70.

72. The isolated nucleic acid of claim 71, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:59.

73. A pharmaceutical composition comprising a multimer of the fusion polypeptide of any one of claims 1, 4, 7, 14, 21, 28, 35, 42, 49, 52, 55, 58, 61, 64, 67 or 70, and a pharmaceutically acceptable carrier.

74. The pharmaceutical composition of claim 73, wherein the multimer is a dimer.

75. An isolated nucleic acid selected from the group consisting of SEQ ID NO: 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57 and 59.

76. A vector that comprises the isolated nucleic acid molecule of claim 75.

77. The vector of claim 76, wherein the isolated nucleic acid molecule is operatively linked to an expression control sequence.

78. A host-vector system for the production of a fusion polypeptide, comprising the vector of claim 77, in a suitable host cell.

79. The host-vector system of claim 78, wherein the suitable host cell is a bacterial cell, yeast cell, insect cell, or mammalian cell.

80. The host-vector system of claim 79, wherein the suitable host cell is a CHO cell.

81. A method of producing a fusion polypeptide that comprises growing cells of the host-vector system of claim 78, under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.